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ABSTRACT OF THE DISSERTATION
Comparison of Receptor Efficacies on Vascular Smooth Muscle Contraction
by
Oommen K George
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, June 2003
Ramon R. Gonzalez, Jr., Chairperson

Vascular smooth muscle contraction involves multiple signal-transduction
pathways, the interrelations of which are not completely understood. Our objectives in
this project were to compare the effects of phenylephrine (ai-adrenergic agonist).
angiotensin II (ATi agonist), clonidine (a2-adrenergic agonist) and moxondine (ct2adrenergic /Ii-imidazoline agonist) on contraction in the rat-tail artery. Functionally, all
these agonists cause contraction, but biochemically there are differences in how the result
is achieved. We wanted to determine the role of protein kinase C (PKC) in the functional
regulation between ATj and cti-adrenergic receptor pathways. In addition, we were
interested in elucidating the effects of moxonidine on the rat-tail artery. Our study
demonstrates that the ai-adrenergic receptor is the major receptor for mediating
contraction in the rat-tail artery. The postsynaptic ot2-adrenergic receptor also plays a
significant role in rat-tail artery contraction, but to a lesser extent than the aj-adrenergic
receptors. Similarly, ATi receptors are involved in rat-tail artery contraction, but to a
lesser extent than the adrenergic receptors, f receptors were not found in rat-tail artery
contraction. The data also suggest that PKC plays a greater role in the contractile
response mediated by AT] receptor than the cci-adrenergic receptor. The ATi receptor
response seems to affect PLD, resulting in PKC effects downstream. We finally, show
xi

that moxonidine, a known Ii/a2-adrenergic agonist, mediates rat-tail artery contraction
via the activation of Gt2-and cci-adrenergic receptors, and not via specific imidazoline
receptors.
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CHAPTER ONE
OVERVIEW OF THE CIRCULATORY SYSTEM
The circulatory system is the main lifeline in the human body. Without it all
function would cease. What the nervous system dreams of, the circulatory system brings
to pass. It does this by providing to each individual cell, in the large and
heterogeneous population of cells in the body, oxygen and other nutrients it needs.
and also by removing carbon dioxide and waste products. It can meet a wide range of
cell demands, and is so self-regulating that there is usually neither excess nor shortage of
substrate.
Blood is the transport medium and flows within the circulatory system. The
circulatory system includes the heart, which is the major pump, and the blood vesselsarteries, capillaries, and veins. The heart and blood vessels supply two different
circulations i.e., the pulmonary and the systemic circulations. The components of the
system work with precise unity, creating physical forces that result in the proper circulation
of blood to every cell.

The circulatory system also delivers molecular messages and

instructions from other cells, distant or nearby. In case of tissue damage, it brings tools for
repair and healing to the site. This is a self-sealing circuit. Even new routes can be
constructed

1,2,3

Historical Perspective
Confusion over the nature of the heart, the blood, and the role of the blood in the
body has existed for centuries. Pliny the Elder, a Roman writer who lived from AD 23-79,
and author of a 37-volume treatise entitled Natural History, wrote "The arteries have no
sensation, for they even are without blood, nor do they all contain the breath of life; and
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when they are cut only the part of the body concerned is paralyzed...the veins spread
underneath the whole skin, finally ending in very thin threads, and they narrow down into
such an extremely minute size that the blood cannot pass through them nor can anything
else but the moisture passing out from the blood in innumerable small drops which is called
sweat."
A century late, Galen, a Greek physician who lived in the second century AD, spent
his lifetime in observation of the human body and its functioning. Galen believed and
taught his students that there were two distinct types of blood. "Nutritive blood' was thought
to be made by the liver and carried through veins to the organs, where it was consumed.
'Vital blood' was thought to be made by the heart and pumped through arteries to carry the
"vital spirits." Galen believed that the heart acted not to pump blood, but to suck it in from
the veins. Galen also believed that blood flowed through the septum of the heart from one
ventricle to the other through a system of tiny pores. He did not know that the blood left
each ventricle through arteries .
Physicians, as well as lay people of many cultures, had their own beliefs concerning
the nature of the heart and circulatory system. While the Greeks believed that the heart was
the seat of the spirit, the Egyptians believed the heart was the center of the emotions and
the intellect. The Chinese believed the heart was the center for happiness. Even our modem
society continues to put emotions under the control of the heart, speaking of having a
broken heart when a loved one leaves, or stealing one's heart around Valentine's Day.
These beliefs continued to be taught and taken as law until an English physician named
William Harvey challenged them in the late 1620's 1’2.
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William Harvey was bom in 1578 in Folkstone, England. The eldest of seven sons,
Harvey received a Bachelor of Arts degree from Cambridge in 1597. He then studied
medicine at the University of Padua, receiving his doctorate in 1602. By all measures,
Harvey was successful. After he finished his studies at Padua, he returned to England and
set up practice. He then married Elizabeth Brown, daughter of the court physician to Queen
Elizabeth I and King James I. This put him in position to be noticed by the aristocracy, and
Harvey quickly moved up the ladder. Eventually, he became court physician to both King
James I and King Charles I. While acting as court physician, Harvey was able to conduct
his research in human biology and physiology. Harvey focused much of his research on the
mechanics of blood flow in the human body. Most physicians of the time felt that the lungs
were responsible for moving blood around throughout the body. Harvey questioned these
beliefs and his questions directed his life-long scientific investigation 2.
Harvey's experiments involved both direct dissection and physiological experiments
on animals. His observations of dissected hearts showed that the valves in the heart allowed
blood to flow in only one direction. Direct observation of the heartbeat of living animals
showed that the ventricles contracted together, dispelling Galen's theory that blood was
forced from one ventricle to the other. Dissection of the septum of the heart showed that it
contained arteries and veins, not perforations. When Harvey removed the beating heart
from a living animal, it continued to beat, thus acting as a pump, not a sucking organ.
Harvey also used mathematical data to prove that blood was not being consumed. Removal
of blood from human cadavers showed that the heart could hold roughly two ounces of
blood. By calculating the number of heartbeats in a day and multiplying this by two ounces,
he showed that the amount of blood pumped, far exceeded the amount that the body could
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possibly make. He based this figure on how much food and liquids a person could
consume. To Harvey, this showed that the teaching by Galen, that blood was being
consumed by the organs of the body, was false. Blood had to be flowing through a 'closed
circuit' instead. Even though he lacked a microscope, Harvey theorized that the arteries
and veins were connected to each other by capillaries. Marcello Malpighi would discover
this theory some years after Harvey's death 2.
Harvey did not allow the beliefs of Galen concerning the role of natural, vital, and
animal spirits and their effects on physiology to affect his objectivity. Instead, Harvey
asked simple, pointed questions, the types of questions that even today are the hallmark of
good scientific research. Harvey asked such questions as why did both the lungs and the
heart move if only the lungs were responsible for causing circulation of blood? Why
should, as Galen suggested, structurally similar parts of the heart have very different
functions? Why did 'nutritive' blood appear so similar to 'vital' blood? These and other.
questions gave Harvey his focus. Harvey's lecture notes show that he believed in the role of
the heart in circulation of blood through a closed system as early as 1615. Yet he waited 13
years, until 1628, to publish his findings in his work Exercitatio anatomica de motu cordis
et sanguinis in animalibus or On the Movement of the Heart and Blood in Animals. Why
did he wait so long? Galenism, or the study and practice of medicine as originally taught by
Galen, was almost sacred at the time Harvey lived. No one dared to challenge the teachings
of Galen. Like most physicians of his day, William Harvey, was trained in the ways of
Galen. Conformation was not only the norm, but was also the key to success. To rebel
against the teachings of Galen could quickly end the career of any physician. Perhaps this
is why he waited. Harvey's hesitation proved well founded. After his work was published,
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many physicians and scientists rejected him and his findings. Using different assumptions
of the amount of blood contained in the heart, scientists argued that the blood could indeed
be consumed. Controversy raged for a full twenty years after publication of "On the
Movement of the Heart and Blood in Animals." Yet, with time, more and more physicians
and scientists accepted Harvey's hypotheses. 12.
Components of the Circulatory System
The components of the circulatory system are:
1. The heart, (dual pump, 2 pumps in series )
2. The arteries, a series of distributed blood vessels; they in part dampen the

pulsatile outflow of blood from the heart to provide for a more continuous flow
of blood to the tissues. The arterioles, because of their smaller internal
diameter, are the major site of resistance to blood flow. Changes in the
diameter of the arterioles determine the amount of blood flowing through a
particular tissue bed, as well as distribution of blood flow among different tissue
beds.
3. The capillaries, an extensive network of very thin-walled vessels that is the

major site of molecular exchange between the blood and the extracellular fluid.
4. The veins, a series of valved collecting blood vessels; they contain the major

portion of the circulating blood volume and, because of the surrounding smooth
muscle, play a major role in regulating the distribution of the blood volume
within the body.
5. The blood provides a vehicle for the rapid movement of cells and molecules
from one part of the body to another.

5

The pathways of the circulatory system consist of two main routes connected in series.
Figure 1 shows that the heart pumps deoxygenated blood from the right heart to the lungs
via the pulmonary arteries and receives oxygenated blood from the lungs to its left heart via
the pulmonary arteries, which it then pumps into the systemic circulation to the rest of the
body. Blood depleted of oxygen, is returned to the right heart, and the cycle repeats. In the
systemic circulation, there are separate pathways to target organs and tissues, all arranged
in parallel. This means that all the blood goes through the right heart, then the lungs, and
then the left heart; but from there, it is divided up among all the organs and tissues ’.

6

Oxygenate'
blood

eoxygenated

Portal system

Figure 1: Components of the Circulatory System
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Overview of the Arteries
Arteries transport blood under high pressure and at high flow rates to the arterioles.
They can do that largely because the arterial system is a pressure reservoir providing a
perpetual force to push blood into the capillaries. Small arteries regulate blood flow and
distribute the precise amount of blood needed by a particular tissue or organ at any given
time. Moreover, while delivering all these various amounts of blood, the arterial system
maintains a stable pressure 1.
Anatomy of the Arteries
Embryologically, the circulatory system originates from mesoderm. The mesoderm
also gives rise to other tissues such as muscles, kidneys and connective tissue.
Examining the anatomy of arteries, we see that the classification of the vascular system is
based on structure and function. The essential functions required of arteries are that they
be tough and elastic enough to handle the high and pulsatile pressure to which they are
subjected. Arteries (especially the small ones) need to be able to vary their internal
diameter size to allow more or less blood flow through, while maintaining their role as
high-resistance vessels.
Arteries have three layers (Figure 2). The innermost intima is a single layer of
lining cells (the endothelium) and an underlying basement membrane called the internal
elastic lamina. The middle layer or media has circular and longitudinal smooth muscle
fibers, and fine elastic fibers interspersed to withstand the pressure within. The outer layer,
the adventitia, has longitudinally directed elastic fibers and collagen (for strength) as well
as fibroblasts, macrophages, nerve fibers, and small blood vessels. As arteries get smaller
the proportion of elastic fibers in the media decreases and the proportion of muscle cells
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increases. Functionally, this is beneficial because the small arteries participate in the
resistance of the hydraulic circuit. In the smallest arterioles the media consist of a single
layer of smooth muscle cells 2’4.
Elastic lamina
(elastic fibers)

Loose
connective
tissue

Smooth
muscle

Endothelial
lining

Basal lamina
Figure 2: Cross-section of an artery
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Components of Vascular Smooth Muscle Cells
The tunica media of a blood vessel contains smooth muscle cells arranged in a
helical pattern. Each smooth muscle cell is spindle shaped approximately 20-60 pm long
by 4 pm wide at the nuclear region. Their contraction results in the cell getting shorter and
fatter. The distinguishing feature of these cells is that the contractile elements are not
arranged in orderly sarcomeres as in skeletal muscle cells. Thus the cells have no
striations.
The basic contractile unit within the cell is a sarcomere-like unit composed of actin
and myosin filaments. Compared with skeletal muscle, smooth muscle contains less
myosin and more actin. The filaments are longer than in cardiac sarcomers, and this
contributes to the high degree of shortening achievable by vascular smooth muscle. Thick
filaments of myosin (length 2.2 pm, diameter 15 nm) are surrounded by thin filaments of
actin (1.5 pm x 7 nm). The apparent ratio of thin to thick filaments in smooth muscle cells
are 10 to 15 actin to each myosin, rather than 2 to 1 as in a skeletal muscle sarcomere1.
In addition to the thick and thin filaments, smooth muscle cells contain a third
network of filaments that form an internal “skeleton”. These intermediate filaments,
along with their associated dense bodies, link the cells so that groups of smooth muscle
cells can contract as a whole.
Like cardiac muscle cells, there are gap junctions between smooth muscle cells
allowing for electrical communication. These gap junctions are formed by the protein
connexin, as in cardiac myocytes. Six connexins in each cell combine to form a narrow,
hollow tube that connects the cytoplasm of one cell to the next. This allows ionic currents
to flow between cells, transmitting depolarization from cell to cell. In small arteries there
10

are also gap junctions between the innermost vascular smooth muscle (VSM ) cells and
endothelial cells. These myoendothelial junctions transmit regulatory, hyperpolarizing
signals from endothelium to vascular smooth muscle cells 1’5.
The cell membrane has numerous tiny invaginations called caveolae.
Immunoelectron microscopy studies have localized both a Ca+2-ATPase and IPs-like
receptor to smooth muscle caveolae. In recent years the discovery of caveolins, a family of
proteins forming the main structural components of caveolae , has witnessed an explosion
of interest in the possible functional roles of caveolae in diverse cell types. Three main
mammalian isoforms of caveolin exist (termed caveolin-1, -2, and -3). Caveolae and
sarcoplasmic reticulum are separated by distance as little as 10 to 40 run. As a result of
these findings, caveolae in the smooth muscle cells may be involved in calcium transport
and in the trafficking of membrane proteins between the interior and cell surface
coordinating an efficient mechanism for smooth muscle contraction 5.
Sarcoplasmic reticulum (SR) is another main component within the vascular
smooth muscle cell. An important function of this structure is to store calcium ions. It is
relatively poorly developed, being 1-4% of the cell by volume. Because the intracellular
calcium store is relatively modest, the cell depends on an influx of extracellular calcium
ions, as well as store release, for normal contraction. This is especially true in small
resistance vessels 1’5. The components mentioned above play a vital role in the
development and regulation of smooth muscle contraction (Figure 3).
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Figure 3: Diagram of the main components within vascular smooth muscle cell
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Overview of Smooth Muscle Contraction
The Ca+2 concentration in smooth muscle cell determines its contractile state. Here,
that state is not “off’ or “on,” contracted or relaxed; instead it may be somewhere in
between, in a whole range of modulations or gradations. For many blood vessels, including
most resistance vessels and arteries, the normal, physiological state is one of continuous.
partial contraction called basal tone. Mechanisms exist to increase the tone
(vasoconstriction) or reduce it (vasodilatation). Contractions can be increased in vivo by
stimulation of sympathetic nerves, which act by releasing norepinephrine, along with some
adenosine trisphosphate (ATP) and neuropeptide Y ( NPY ). Contraction can also be
increased by circulating hormones such as norepinephrine and epinephrine and by ‘local
hormones’ such as endothelin released from the endothelium. In the laboratory, for
experimental purposes, depolarizing the smooth muscle cell with an isotonic potassium
chloride solution can induce contraction

1,15

Cu 2 —a Regulator
In cardiac myocytes, when Ca+2 concentration is high, the binding sites on actin for
myosin heads are available and crossbridges form. Sarcomeres progressively shorten, and
cardiac myocytes contract. When Ca+2 levels fall, the binding sites on actin are no longer
available to myosin heads for attachment, and the binding stops. The sarcomeres lengthen
and the cardiac myocytes relax.
In the smooth muscle cells, Ca+2 is also the regulator. However when Ca+2
concentration rises, the myosin arm is phosphorylated, allowing crossbridges to form.
cycle, and continue to cycle. The contractile units shorten and the smooth muscle cells
contract. When Ca+2 concentrations fall, the myosin arm is dephosphorylated. No new
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attachments of myosin heads to actin occur. But those already established proceed through
the cycle at a slowed rate. The attachment lingers (latch phenomenon). This allows the
contractile units in the smooth muscle cell to sustain partial contraction, or tone, for a time
and to do it with little energy expended, because ATP is not being continually consumed.
Overall, the latch phenomenon reduces the energy cost to 1/3 00th the amount of ATP that
striated muscle would need to sustain the same force

1,14,15

The importance of Ca in activating vascular smooth muscle contraction was first
established more than 35 years ago with the demonstration that glycerinated (skinned)
fibers developed force when the free [Ca ] in the bathing medium was increased over the
range 0.18pM-l pM 1. Hartshome and others discovered that myosin light chain kinase,
the enzyme responsible for myosin phosphorylation, requires Ca+2 and calmodulin for
activity. This led to the proposal of the mechanism that regulation of smooth muscle
o

contraction occurs by phosphorylation and dephosphorylation of myosin . In 1985, DeFeo,
Morgan and others showed that neuronal or hormonal stimulation of the muscle results in
an increase in cytosolic free [Ca+2] from ~140 nM to 500-700 nM. This results in Ca+2
binding to calmodulin (which is similar in structure to troponin): four Ca ions bind per
calmodulin molecule and induce a conformational change, which involves exposure of
site(s) of interaction with a target protein, in this case myosin light chain kinase (MLCK).
When activated, MLCK transfers a phosphate from ATP on to the arm of myosin (two 20kDa light chain subunits of myosin (LC20)). This phosphorylation reaction triggers cycling
of myosin heads along the actin filaments and the development of force or shortening of the
muscle 8,9,1 °. This is reflected in vitro by a marked actin activation of the myosin Mg+2ATPase activity. When the intracellular Ca

levels decrease, Ca -calmodulin-MLCK

14

complex is dissociated, and myosin phosphorylation ceases. Myosin is dephosphorylated
by myosin light chain phosphatase (MLCP), and the muscle relaxes 1
-f-9

It is clear that a rise in the concentration of cytosolic free Ca

is the major trigger

for the contraction of smooth muscle. Smooth muscle contraction is partially regulated by
electromechanical coupling mechanisms, which involve membrane depolarization resulting
in activation of voltage-gated Ca channels in the sarcolemmal membrane. In addition,
contraction is regulated by pharmacomechanical coupling mechanisms, whereby agonist
can induce contraction by activation of second messenger systems without depolarizing the
membrane i3.
Electromechanical Coupling
Electromechanical coupling depends on voltage-regulated Ca+2 channels. Smooth
muscle cells have no need for T-tubules to transmit an action potential deep inside. Instead
of T-tubules, smooth muscle cells have small shallow sacs in the plasma membrane
(caveoli). Also, smooth muscle cells do not have fast sodium channels, so the change in
membrane potential during an action potential is chiefly due to a rapid increase in Ca +2
permeability

14,15

.

The resting membrane potential across smooth muscle cell plasma

membrane is usually in the range of-50 mV to - 60 mV. This is largely an expression of
the membrane’s potassium permeability. When the membrane potential is less negative,
(that is depolarized) more voltage regulated Ca+2 channels open and Ca+2 enters the cell.
This results in greater smooth muscle contraction, vasoconstriction, and reduced tissue
perfusion. For example, stimulation by K+ induces depolarization of the cell membrane,
which opens voltage-gated Ca+2 channels causing Ca+2 influx to increase cytosolic [Ca+2].
Conversely, if the membrane potential is more negative (hyperpolarized), more of the
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Ca

4-9

4-9

channels close, and the Ca

levels in the cell falls. This results in smooth muscle

relaxation (or less contraction), vasodilatation, and increased tissue perfusion.

12,13,15

Pharmacomechanical Coupling
Phamacomechanical coupling involves a wide range of extracellular signals altering
cytosolic [Ca+2], and the contractile state of smooth muscle, without affecting the
membrane potential. This type of coupling is initiated by activation of specific receptors in
the vascular smooth muscle membrane, such as adrenergic receptors. Many large vessels,
such as the pulmonary artery, dot not fire action potentials because they possess relatively
4_2

.

_|_2

few voltage sensitive Ca channels, so inward Ca current never succeeds in
overwhelming the outward K+ current. In such vessels the superfusion of norepinephrine at
low concentrations causes a sustained contraction with little membrane depolarization.
Moreover, even action potential generating vessels such as the portal vein can be induced
to contract without action potentials if their voltage sensitive calcium channels are blocked
by nifedipine, a calcium channel antagonist

16,18

Figure 4 shows a flow chart of multiple pathways by which pharmacomechanical
coupling can enhance vascular smooth muscle contraction. One mechanism is the opening
of the receptor-operated channels. This allows extracellular calcium ions to flow into the
cell. The second mechanism involves activation of G-protein coupled receptor systems,
which activate effector enzymes like phospholipase C and phospholipase D to release
second messengers that regulate cytosolic Ca+2 and other pathways that sustain smooth
muscle contraction. The focus of this dissertation will be to compare and determine the Gprotein coupled receptor response of various agonists mediating contraction in the proximal
rat-tail vascular smooth muscle.

We will begin chapter two with a comprehensive review

16

of signal transduction pathways that are activated which lead to vascular smooth muscle
contraction.

;
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Figure 4: Flow chart of multiple pathways by which an agonist can enhance
vascular smooth muscle contraction. The extent to which the various parallel
pathways are activated varies between vessels. VSCC, voltage-sensitive
calcium channel; ROC, receptor operated channel; IP3, inositol trisphosphate;
MLC, myosin light chain.
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CHAPTER TWO
SIGNAL TRANSDUCTION
Signal transduction is an important component of pharmacomechanical coupling. A
signal or stimulus may originate in the external environment or within the cell. This signal
may be an electrical pulse (action potential), or a chemical signal. The expression, signal
transduction, first made its mark in the biological literature around 1974. In the Oxford
English Literature (2nd Edition), the word transduction means ‘the action of leading or
bringing across’. Cell signaling requires not only electrical and extracellular signal
molecules, but also a complementary set of receptor proteins in each cell that enable it to
bind and respond to the signal in a characteristic way

19,20,21

. Figure 5 depicts the agonist->

receptor-> transducer-^ effector signal transduction components involved in the
biochemical and physiological effect of drugs, or signals, and their mechanism of action.

G-protein coupled receptors
Extracellular side
N

Substrates
r

Plasma tnembrai

i -f~
Effector
PLC/PLD

Cytosolic side

Figure 5: Components of G-protein coupled receptor systems. GTP, guanosine
trisphosphate; GDP, guanosine diphosphate; PEC, phospholipase C; PLD, phospholipase
D; PI, phosphatidylinositol; PS, phophatidylserine; PE, phosphatidylethanolamine;
PC, phophatidylcholine.
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Plasma membrane
In vascular smooth muscle cells, the receptor proteins that regulate contraction are
in the plasma membrane. Lipids and proteins, both chemical components of the
membrane, are able to move and interact, due to the fluid state of the membrane. The
plasma membrane and its components are the link to the outside, controlling the movement
of substances into and out of the cell and serving as a means of communication19.
Phospholipids and Substrates
Phospholipids are synthesized in the smooth endoplasmic reticulum. They are
transported to the Golgi apparatus and then to membranes of organelles or to the plasma
membrane. In addition, they may be secreted from the cell by exocytosis. Hydrolysis of
phospholipids in response to extracellular signals takes place mainly at plasma and nuclear
membranes. Phospholipids are compounds composed of an alcohol that is attached by a
phosphodiester bridge to either diacylglycerol or to sphingosine. Like fatty acids.
phospholipids are amphipathic in nature. Each has a hydrophilic head (the phosphate group
plus whatever is attached to it—serine, ethanolamine, choline, inositol, etc.) and a long,
hydrophobic tail (containing two fatty acid chains). The distribution of these lipids varies
between different subcellular compartments and they are asymmetrically distributed
between the two membrane leaflets, the outer (extracellular) leaflets of the plasma
membrane contains predominantly phosphatidylcholine (PC) and the inner (cytoplasmic)
leaflets contains essentially phosphatidylserine (PS), phosphatidylethanolamine (PE) and
phosphatidylinositol (PI). Their ability to form a lipid bilayer spontaneously, provides a
permeability barrier between extracellular and intracellular compartments, which is
essential to cell survival

19,20
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Phospholipids that contain glycerol are called phosphoglycerides or glycerolphospholipids. All phosphoglycerides contain phosphatidic acid (diacylglycerol with a
phosphate group on the third carbon). Phosphatidic acid (PA) is the simplest
phosphoglyceride, and is the precursor of the other members of this group. They are as
follows:
Serine + PA -> phosphatidylserine (PS);
Ethanolamine + PA -> phosphatidylethanolamine (PE);
Choline + PA -> phosphatidylcholine (PC);
Glycerol + PA -> phosphatidylglycerol (PG);
Inositol + PA -> phosphatidylinositol (PI).
In addition, the composition of the outer and inner leaflets determines the types of lipid
hydrolyzing activities required to generate second messengers 19,20.

Structures are

illustrated below (Figures 6 and 7).

o

Phosphatidic acid

Figure 6: Structure of 1,2 -diacylglycerol-3-phosphate, or phosphatidic acid, the backbone
of lipid substrates in the plasma membrane.
22

Figure 7: Structures of the major phosphoglycerides found in the membrane,
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine
(PE), phosphatidylcholine (PC), and phosphatidylglycerol (PG).
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Phospholipid Turnover
The realization that phospholipids could participate in signal transduction
mechanisms came from observations that agonist induced hydrolysis of a minor membrane
phospholipid, phosphatidylinositol 4,5, -bisphosphate (PIP2). This reaction catalyzed by a
phosphoinositide-specific PTC (PI-PLC) enzyme, generated two intracellular second
messengers:
1) inositol 1,4,5-trisphosphate (IP3),
2) diacylglycerol ( DAG ).
The agonist-induced breakdown of PIP2 is linked to the subsequent resynthesis of
phosphoinositides (phosphatidylinositol, phosphatidylinositol-4-phosphate, PIP2), resulting
in a phosphoinositide cycle. In 1953 this synthetic response ( P incorporation into
phosphoinosoitides) was first observed by Hokin and Hokin, when a cholinergic agonist
was added to pancreatic slices. In 1975 Michell provided significant insight into the
physiological significance of this phosphoinositide cycle when he observed that most
agonists that stimulated phosphoinositide breakdown and resynthesis also mobilized
intracellular calcium 22,23
Phospholipid turnover in the plasma membrane allows lipids to act as a reservoir for
signaling molecules, and, when a receptor binds its appropriate activating ligand, a chain of
events are initiated which leads to the breakdown of these lipids and the release of second
messengers. The capability of phospholipids to be hydrolyzed is made possible by
phospholipases, which are membrane associated proteins found in all tissues and pancreatic
juice

19

.
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Types of Phospholipases
Phospholipase A / and Phospholipase A2
Phospholipases are enzymes, which are responsible for degrading and remodeling
phospholipids.

There are four types of phospholipases. They are classified according to

the bond cleaved in a phospholipid. Each enzyme cleaves at different position on the
phospholipid backbone (Figure 8). Phospholipase Ai catalyses the hydrolysis of the fatty
acyl group on the first (sn-1) position of glycerol. Phospholipase A2 catalyses the
hydrolysis of the fatty acyl group on the second (sn-2) position of glycerol. Both these
enzymes are involved in producing primarily arachidonic acid and lysophospholipid.
Arachidonic acid is a major precursor to leukotrienes, thromboxanes and prostaglandins.
Lysophospholipid is a precursor to platelet activating factors. Biochemically, an
unsaturated fatty acid is removed from the 2 position of a phospholipid like a
phosphatidylcholine/inositol by phospholipase A2. Then the fatty acid is replaced with
alternative fatty acids by fatty acyl-CoA transferase. This mechanism is used to create the
unique dipalmitoylphosphatidylcholine, which is an important lipid component of lung
surfactant—the extracellular fluid layer lining the alveoli involved in reducing alveolar
surface tension

.
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Figure 8: A simplified scheme of phospholipase cleavage sites involved in the production
of phospholipid substrates.
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Phospholipase C
The third type of phospholipase enzymes is Phospholipase C (PLC). Historically,
this enzyme has been studied since the 1950s.

In 1975, Michell, and others, elucidated

that PLC is a key enzyme in agonist-stimulated phosphoinositide metabolism and calcium
signaling. Phospholipase C cleaves the bond between glycerol and a phosphate . Under
the control of cell surface receptors, these enzymes hydrolyze the highly phosphorylated
lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two intracellular products:
-4-9

IP3 a universal Ca mobilizing second messenger, and DAG. DAG activation of protein
kinase C in many cell systems is one of the earliest key events in the regulation of various
cell functions by a number of extracellular signaling molecules, particularly in vascular
•
84
smooth muscle regulation
.

Since the early 1990’s 10 mammalian PLC isozymes have been identified. All
single polypeptides can be divided into three types: (3,y, and 5, which were identified based
on their cDNA sequences. Examination of the amino acid sequence, starting at the N
terminus, reveals that all the PLCs possess a pleckstrin homology (PH) domain, which
consist of some 100 amino acid residues, and are shown to mediate protein-protein or lipidprotein interactions. PLCs also have a stretch containing EF-hand motifs, which are
thought to be common Ca -binding regions on proteins. All forms of PLCs possess C2
domains in the vicinity of the C-terminus, which can bind phospholipids in a Ca+2dependent fashion. The catalytic domains, split into X and Y sub-domains, possess high
sequence similarity24,25. Finally, the long (-500 amino acids) C-terminal extension of
PLCp (Figure 9) enables its association with the membranes, and allows for regulation by
Gaq/i 1 family of G-proteins.

28

PLCpl
domain

domain

EF hand
region

Catalytic
Domain

Figure 9: Sequence diagram based on PLC(3 isoform, thought to regulate hydrolyze PIP2 to
IP3 and DAG in vascular smooth muscle contraction 85 .
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Phospholipase D
Phospholipase D (PLD) is the fourth type of phospholipid enzyme. PLD is
widely expressed and has been reported in species ranging from bacteria, to yeasts, plants
and mammals. In 1947, Hanahan and Chaikoff first demonstrated the activity of PLD in
plant tissue. They identified an enzyme in carrot tissue which was capable of splitting the
phospholipid molecule at its ester linkage between the nitrogenous base and the
phosphoric acid group. In the late 1950’s Oils and Hubscher suggested the presence of
PLD in the liver. During the mid seventies, Satio and Kanfer showed that soluble
preparations of enzymes from brain released choline and ethanolamine from PC and PE,
respectively. In addition, biochemical studies have identified specific
transphophatidylation reactions, which provide strong evidence for PLD activity in
various tissues. This reaction involves primary short chain alcohols (e.g., methanol,
ethanol, 1 -propanol, n-butanol), which can be substituted for water in a competing
transphosphatidylation reaction. The product of PLD-catalyzed, transphosphatidylation
reaction is the corresponding phosphatidic acid alkyl ester, or phosphatidyl-alcohol29.
(Ligure 10).

Relative to PA, a phosphatidyl-alcohol is metabohcally stable, and tends to

accumulate in cells upon PLD activation. Being an ‘abnormal’ phospholipid, changes in
cellular phosphatidyl-alcohol level are readily detectable. Because of these properties
phosphatidyl-alcohols are very useful markers of PLD activation in vitro and in vivo
studies

. Detailed biochemical and molecular biological analysis have provided a

springboard for the cloning of genes encoding mammalian PLD1 and PLD2.
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Figure 10: Depicts the biochemical reaction involving Phospholipase D catalyzed
hydrolysis called the transphosphatidylation reactions. The structures of the PLD
substrate, phophatidylcholine, and the products of hydrolysis and transphosphatidylation
reactions catalyzed by PLD are shown.
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In the last five years, investigators have identified proteins that regulate phospholipase D
activity. They include monomeric G-protiens (ART and Rho) and protein kinase C. In
vascular smooth muscle cells, PLD1 provides another, less transient, source of DAG, by
cleaving PC to form phosphatidic acid and the water-soluble choline. Removal of the
phosphates (by phosphatidate phosphohydrolase) produces the DAG 24. The discovery
of these regulatory proteins and the availability of compounds (calphostin C and
chelerytherine chloride) that inhibit these proteins make possible for us to identify the
functional nature of these membrane proteins in effecting smooth muscle regulation
downstream. Figure 11 shows the molecular structure of phospholipase Dl.

PKC
Rho
pPp

PLDl

HKD

HKD

Catalysis

Figure 11: Structure of mammalian PLDl. Regions of conserved sequence are boxed.
PX, phox homology domain; PH, pleckstrin homology domain; regions I, II, III, and IV,
regions of sequence conserved among all PLD isoenzymes; Regions of PLDl broadly
identified in stimulation of catalytic activity by PKC and Rho are lined and the PI(4,5)P2
interacting site is arrowed.
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Signal Transduction by Cell-Surface Receptors
The basic mechanism for signal transduction is initiated by ligand binding to
receptors located on the plasma membrane. The cell surface receptor responds to its
specific ligand by a conformational change that triggers a transmembrane signal. There
are three main families of cell-surface receptors, each of which transduces extracellular
signal in a different way. The first two classes involve receptors coupled directly to
effector molecules: Ligand-gated ion channels (i.e., cholinergic nicotinic receptors) and
receptors with catalytic activity (i.e., insulin receptors). Ion channel-linked receptors are
ligand-gated ion channels that open or close briefly in response to the binding of a signal
molecule or neurotransmitter. Receptors with catalytic activity are enzyme-linked
receptors. These act either directly as enzymes or are associated with enzymes (usually
protein kinases) that phosphorylate specific proteins in the target cell. The third class
involves receptors coupled to effectors by a second messenger. These are G-protein1 inked receptors, which indirectly activate or inactivate plasma-membrane-bound
enzymes or ion channels via trimeric GTP-binding proteins or G-proteins 34.
G-protein coupled receptors (GPCRs) form the largest family of cell-surface
receptors that are found in many cells, especially in vascular smooth muscle cells. Seven
membrane-spanning domains with an extracellular N terminus and a cytoplasmic C
terminus characterize GPCRs. They mediate responses to an enormous diversity of
signal molecules, including hormone, neurotransmitters, and local mediators 42.
G-proteins, also called transducers, are guanine nucleotide-binding proteins. This
family of proteins relays signals from each of more than 1000 different membrane
receptors, to many different intracellular targets, including ion channels and enzymes.
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The basic scheme starts with an agonist binding to a specific receptor on the cell
membrane. The G-protein lies just beneath the plasma membrane. It consists of three
subunit parts: alpha (a), beta (|3), and gamma (y). When inactive, the a subunit is bound
to guanosine diphosphate (GDP), and the a -GDP is in turn bound to the p and y
complex. Agonist binding to the extracellular domain of the receptor activates this
system. GDP is released and guanosine trisphosphate (GTP) binds to a. Now the aGTP unit separates from the P-y portion and both (a-GTP and py) separate from the
receptor. Each part is free to activate a specific target or set of targets (Figure 13). The
GTPase cycle, first perceived in the process of visual photransduction and p-adrenergic
activation of adenylyl cyclase, is central to many important signal transduction
mechanisms 40. The GTP-bound form of the a-subunit is required to activate effector
enzymes such as adenylyl cyclase. This catalyses the conversion of ATP to cyclic
adenosine monophophate (cAMP) and activates phospholipase C, activated PEG cleaves
IP3 and DAG from PIP2, major players in smooth muscle regulation.

34

41,42

Figure 12: Basic cycle for GTP binding and GTP hydrolysis. R, receptor; P, phosphate;
GTP, guanosine trisphosphate; GDP, guanosine diphosphate.
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Diversity of G-proteins
The diversity of the heterotrimeric G-proteins is principally a function of their asubunits. Four families of these proteins, termed s, i, q and 12/13, have been proposed
based on amino acid sequence comparisons. The Gas class contains Gasand Ga0if,
which are 88% identical. Both proteins activate adenylyl cyclase, and are sensitive to
cholera toxin. They have wide tissue distribution 34.
The Gctj class contains Gocm, Goti-2, and Gcti-3. These proteins inhibit adenylyl
cyclase. Gati and Gat2 are expressed in photoreceptors. Ga0_i Ga0.2 and Gaz are
expressed in the brain. Members of the Goci and Ga0 subfamilies are implicated in the
regulation of ion channel activation and potentiating the activity of ERK (extracellular
signal regulated kinase). With exception to Gaz, all the other members of this class are
pertussis toxin sensitive 30,31
The Gctq class contains five family members, Gai 1, Ga^, Gais, Got]5, and Gaq
These closely related proteins are neither pertussin or cholera toxin sensitive. Gaq and
Gcti 1 are widely expressed in mammalian tissues, and the a subunits of the Gccq/i ] family
activate PLCp, found in vascular smooth muscle 32 .
The final class of pertussis toxin- and cholera toxin resistant Ga subunits contains
two proteins, Gai2 and Ga^

These a-subunits are widely expressed. The functions of

the two proteins have not been clearly defined. There is emerging evidence that Gai2/i3
proteins have been implicated in the regulation of phospholipase D, a possible effector
involved in the late or delayed response of vascular smooth muscle contraction

33,34

There is now emerging evidence to suggest that G protein-coupled receptor
activation of various effectors can also be mediated by py subunits. There are 5 P
36

subtypes sharing 50-90% identity (35 kD/39 kD) and at least 12 subtypes of y (5-10 kD).
G(3y regulates adenylyl cyclase 35, PLC-(3 36, Mitogen Activated Protein (MAP) kinases
37

, and mediates beta-adrenergic receptor kinases (|3ARK) . It is now clear, from a

functional level, that all heterotrimeric G-proteins behave as if they were a dimeric
combination of an a and an inseparable py-subunit pair. Py-Subunits have the following
functions:
a)

They ensure the localization, effective coupling and deactivation of the
a-subunits.

b)

They regulate the affinity of the receptors for their activating ligands.

c)

They reduce the tendency of GDP to dissociate from the a-subunits.
thus stabilizing the inactive state.

d)

They interact directly with some downstream effector systems

e)

And, they regulate receptor phosphorylation by specific receptor
kinases 35.

Physiological regulation of G protein-linked receptors allows for integration of signals
that directly or indirectly effect the signaling from the receptor-->G-protein-->effectors.
In the regulation of vascular smooth muscle contraction, the type of G-protein activated.
will result in promoting a particular type of phospholipase to release a second messenger.
that will either potentiate, or attenuate early and late phase of pharmacomechanical
coupling.
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Overview of Receptors
In a system where the receptor is in a dynamic equilibrium between an active and
inactive form, a ligand that binds to the receptor will shift this equilibrium to either the
active or the inactive conformation. Thus, a ligand, will either increase the signaling, if it
has highest affinity for the active confirmation, or decrease the signaling activity, if it has
highest affinity for the inactive confirmation 51.
Among the seven transmembrane receptors (7TMR), a few highly conserved
residues are confined almost entirely to the hydrophobic membrane spanning regions.
The exposed segments vary in length from 7 up to 595 residues for the N-terminus, 12 to
359 residues for the C-terminus and 5 to 230 residues for the loops. It was generally
accepted that receptor activation requires the actual binding of an agonist. The binding of
a ligand is understood to induce a change in receptor conformation, such that only in this
state does it communicate with its affiliated GTP-binding protein 51. Our study will test
the effects of the following ligands: phenylephrine, clonidine, moxonidine, and
angiotensin II, and their effects on activation of adrenergic, angiotensinergic, and
imidazoline receptors resulting in vascular smooth muscle contraction.
Alpha-adrenoceptors
The contraction of vascular smooth muscle by a-adrenergic agonists, particularly
norepinephrine and epinephrine, is a biologic phenomenon that extends across species
lines and heterogeneous vascular beds. It is a fundamental excitatory response, mediated
by the a-adrenoreceptor, of all vascular beds. Alpha-receptor classification has been
based on pharmacologic response to receptor agonists and antagonists. More recently.
assays of radioligand binding have been used successfully to determine affinities of
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various drugs for a-adrenoreceptors, the number of receptors in a given tissue, and alphareceptor subtypes.

For example, the standard equation for specific radioligand binding

to receptors is:

Y= ((Bmax)(X) / X + Kd)) + (NS)(X)

Units
Variable
X
Y
Bmax
Kd

NS

Comments

Usually nanomolar
Cpm; dpm; fmol/mg protein
Same as Yaxis; i.e., cpm;
dpm; fmol/mg protein
Same as X axis; i.e.,
concentration units
Same as Y axis; i.e., cpm;
dpm; fmol/mg protein

Concentration of unlabeled drug
Total binding of radioligand
Maximal density of binding sites for the
radioligand
Equilibrium dissociation constant of the
radioligand.
Fraction of the total binding that is non
specific binding. Constrained to be
greater than zero,___________________

Table 1: Description of standard equation used for radioligand binding to receptors.

Implicit in pharmacologic methods for receptor identification are certain
limitations. Pharmacologic differentiation of receptor subtypes depends on agonist or
antagonist specificity; therefore, changes in the receptor microenvironment or functional
changes that result in exposure of different binding sites on the same receptor cannot be
easily distinguished from new and distinct receptor populations. In addition, most
smooth muscle preparations include endothelium, connective tissue, and neuronal
elements, which indirectly influence pharmacologic responses to extracellular agents or
ligands

52,53
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In 1948, Alquist classified adrenergic receptors into a and (3 subtypes. The
existence of beta subtypes (pi and p2) were first recognized in 1968, and two different
alpha subtypes (cti and 0C2) were discovered in the 1970s. The subsequent demonstration
of alpha-receptor populations on nerve terminals (prejunctional) that could be
distinguished from smooth muscle (postjunctional) surface receptors resulted in the
receptors being sub-classified into oci and «2, respectively. For example, phenylephrine
(THE) more selectively activates a 1-adrenergic, and clonidine activates a.2-adrenergic
receptors. Similarily, aj-adrenergic receptors can be distinguished from a2-adrenergic
receptors by the relative affinity of the antagonist prazosin (cti > aj) and yohimbine (0C2 >
ct]). Most vascular smooth muscle contains both oi-and 02- adrenergic receptors, with
the exception of the cerebral circulation, where a2-adrenoceptor is prevalent 52,53,54,56
The post-synaptic vascular o-adrenergic receptors are responsible for smooth
muscle contraction. In the vascular smooth muscle, a 1-adrenoceptors are located
intrasynaptically, and function in response to neurotransmitter release. For non-vascular
smooth muscle they can be found on the liver, where they cause hepatic glycogenolysis
and potassium release. On the heart they mediate a positive inotropic effect. They also
cause relaxation of GI smooth muscle and decrease salivary secretion.
Alpha2-adrenoceptors are found in both the central and peripheral nervous
system. They are found both pre- and postsynaptically and serve to produce inhibitory
functions. Presynaptically, a,2-receptors inhibit the release of norepinephrine and thus
serve as an important receptor in the negative feedback control of norepinephrine release.
Postsynaptically, ci2-adrenoceptors are located on pancreatic (3 cells, platelets, and the
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smooth muscle of blood vessels. Activation of these receptors causes decrease in insulin
secretion, platelet aggregation and blood vessel constriction

56,57

All a-adrenoceptors are G-protein coupled to activate various effectors resulting
in activation of different mechanisms, depending upon tissue type. For example,
activation of a ]-adrenoceptors in the rat-tail will result in stimulating phospholipase C,
that phosphorylates PIP2 to produce IP3 and DAG, which results in the rise of
+2

intracellular Ca

and the activation of calcium channels respectively. However,

activation of ct2-adrenergic receptors result in activating Gi type of G-protein, which acts
to inhibit adenylate cyclase and so reduce the activity of protein kinase A. Sensitivity of
the contractile process to Ca
contraction

is potentiated, leading to vascular smooth muscle

.

Beta-adrenoceptors
The j3-adrenoceptors were initially divided into p 1 and p2-adrenoceptors defined in
terms of agonist potencies. Betaj-adrenoceptors demonstrated equal affinity for
epinephrine and norepinephrine while p2-adrenoceptors displayed a higher selectivity for
epinephrine than norepinephrine. Pi-receptors are largely postsynaptic and located
mainly in the heart but also found in platelets, the salivary glands and non-sphincter part
of the gastrointestinal tract. They can, however, be found presynaptically. Activation
causes an increase in the rate and contractile force of the heart, relaxation of the non
sphincter part of the gastrointestinal tract, aggregation of platelets and amylase secretion
from the salivary glands. Presynaptically, their activation causes an increase in
norepinephrine release.

41

Beta2-adrenoceptors are mainly post synaptic and located on a number of tissues
including blood vessels, bronchi, gastrointestinal tract, skeletal muscle, liver and mast
cells. Activation results in vasodilatation, bronchodilation, relaxation of the
gastrointestinal tract, glycogenolysis in the liver, tremor in skeletal muscles and
inhibition of histamine release from mast cells

;

57,59

ps-adrenoceptors, expressed predominately in adipose tissue activation, are
proposed to be involved with norepinephrine induced changes in energy metabolism via
lipolysis and thermogenesis. For all p-adrenoceptors, transduction is via G-protein
coupled to the intracellular second messenger adenylate cyclase

57,58,59

Figure 13 shows an overview of the signaling mechanisms of the different adrenergic
receptors found in vascular smooth muscle system.
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Figure 13: Flowchart of the adrenoreceptor family. They are divided into three
subfamilies based on pharmacological properties, structural homology, and signaling
mechanisms.
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Angiotensin II Receptors
Another type of receptor found in the rat-tail similar to adrenergic receptors is the
Angiotensin II (Ang II) receptor. Ang II, the dominant effector of the renin-angiotensin
system, regulates numerous physiological responses, including salt and water balance.
blood pressure, and vascular tone. Angiotensin II is produced systemically and locally in
the vessel wall. Angiotensinogen is acted upon by renin to produce the decapeptide
Angiotensin I (Ang I). This decapeptide (Ang I) is then cleaved by Angiotensin
converting enzyme (ACE) to yield the octapeptide Angiotensin II. Ang II binds to at least
two high-affinity receptors designated AT] receptor and AT2 receptor

60,62

The structure of the AT 1 receptor shows that it is a member of the seven
transmembrane spanning, G protein-coupled receptor family. They are composed of 359
amino acids with a molecular mass of about 41 kDa. The extracellular regions.
composed of the N terminus, and the three extracellular loops, contain three Nglycosylation sites and four cysteine residues.

The human AT\ receptor contains 359

amino acids, the sequence of which is 95% identical with those of the rat and bovine AT]
receptors

61,63

The AT] receptor mediates virtually all of the known physiological actions of Ang
II in cardiovascular, renal, neuronal, endocrine, hepatic, and other target cells. These
actions include the regulation of arterial blood pressure, electrolyte and water balance,
thirst, hormone secretion, and renal function 65.
Ang II binding to the AT] receptor induces a conformational change in the
receptor that promotes its interaction with the G protein(s), which in turn mediates signal
transduction via the several second messenger pathways. These include enzymes, such as
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phospholipase C, phospholipase D, phospholipase A2, adenylyl cyclase, and ion channels.
such as L-type and T-type voltage-sensitive calcium channels. The cellular responses to
AT] receptor signaling include smooth muscle contraction, adrenal steroidogenesis, and
aldosterone secretion, neuronal activation, neurosecretion, ion transport, and cell growth
and proliferation

60,64

It is suggested that the AT2 receptor counterbalances the effect of the AT]
receptor in vitro as well as in vivo. The activation of AT2 receptor results in the
inactivation of MAPK, antiproliferation, promotion of apoptosis, differentiation and
regeneration, opening of delayed-rectifier K channels and closing of T-type Ca channels.
There-expression of the AT2 receptor in various diseases suggests a role of this receptor
in pathophysiology 65. For example, a report119 suggests that the AT2 isoform of the
angiotensin II receptor may be involved in the myointimal hyperplasia following vascular
injury.

Although Ang II is a potent vasoconstrictor, particularly in the renal arteries, it is
not known clearly how effective Ang II is in inducing vasoconstriction in rat-tail artery. It
is know that AT ] receptor subtype is expressed in the rat-tail, but its dominance in
inducing contraction is not clear.
Imidazoline Receptors
Another receptor we will be looking at in regards to vascular contraction is the
imidazoline receptor and its effect in the rat-tail artery. Imidazoline binding sites are
non-adrenergic receptors. Imidazoline (b) receptors are found mainly in the brainstem.
adrenal medulla and kidney. The presence of h receptors is uncertain, because no one
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has shown the presence of this receptor in the rat-tail. Most vascular vessels contain
adrenergic receptors, particularly in the rat-tail.
Imidazolines are compounds with five-member nitrogenous rings. In 1984.
Bousquet introduced the concept of imidazoline binding sites. It was first characterized
by radioligand binding assays using membranes from brain. These preparations consisted
of rostral ventrolateral medulla (RVLM), the brainstem site of action for imidazoline
antihypertensive agents 67. [3H] Clonidine, a cti-adrenergic agonist was found to label not
only ot2-adrenergic receptors, but also a novel population of nonadrenergic binding sites
recognized to show affinity towards imidazolines

68,70

. These imidazolines sites do not

recognize catecholamines, thus clearly distinguishing them from adrenergic receptors.
Two major subtypes of imidazoline binding sites were characterized based on their
affinity for clonidine (I}-imidazoline binding sites) and idazoxan (Ii-imidazoline binding
sities)

66,67,68,69

Imidazoline binding sites of the fi subtype have been characterized not only in
RVLM, but also in the peripheral nervous system, including adrenomedullary chromaffin
cells and carotid body, and in clonal neuronal cells such as PC 12 cells 71 .
The C site is associated with mitochondrial monoamine oxidases (MAO), but this
interaction is not well understood. It is not clear whether they are a true cell surface
receptor 72 .
In the rat-tail vascular model, we wanted to see if the imidazoline receptor is
involved in vascular contraction. If so, is it working through fi or ai- or a2-adrenergic
receptors or both receptor types?
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Moxonidine
Like other imidazolines, moxonidine was initially described as an a2-adrenergic
agonist. However, moxonidine is relatively weak compared with classical (X2-adrenergic
agonist such as clonidine and guanabenz. Moxonidine is an antihypertensive agent with
affinity for f and ot2-adrenergic sites. It has been tested in clinical trials for anti
hypertensive efficacy since the early 1980s. These studies demonstrate that moxonidine
reduces blood pressure in patients with mild to moderate hypertension, with an efficacy
comparable to that of clonidine. Moxondine exerts other effects in animal models such
as reducing cardiac hypertrophy, and increasing sodium and free water excretion in rats
but not humans. In spontaneously hypertensive obese rats, moxonidine improves glucose
tolerance and reduce levels of triglycerides, cholesterol and insulin

71,118

. There is no

available literature establishing f receptors in vascular smooth muscle. In addition, the
type of a-adrenergic receptor activation is in question, particularly in the rat-tail model.
Protein kinase C
Recent studies show that adrenergic and angiotensinergic mediated contraction of
vascular smooth muscle may occur by the activation of two distinct protein-kinase
dependent pathways (i.e. IP3 linked MLCK and/or PKC). However, at what phase (early
or sustained) in the modulation of pharmacomechanical coupling this occurs is
controversial. Most of the work in this area has been done in cerebral vascular tissues
and tissue cultures, i.e. A7r5 rat aortic smooth muscle cells. Little work has been
conducted on intact tissue, like the proximal rat-tail vascular smooth muscle.
Protein kinase C was identified in the late 1970s as a cyclic nucleotideindependent protein kinase present in bovine cerebellum
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73

. As first described, this

activity appeared to be the product of limited proteolysis by a calcium-dependent
protease 74, but shortly afterward it was found to be activated by Caf2 (50 pmol/1) and
phospholipids with no need of proteolysis

. More significantly, the activity of this

protein kinase could also be stimulated by the addition of a small quantity of
diacylglycerol (DAG)76. This enzyme became a focus of interest when it was found to be
the predominant intracellular target for the active principles of croton oil, long recognized
as a skin irritant having tumor-promoting capacities 11. Such phorbol esters activate
PKC, substituting for the physiological DAG. Phorbol myristate acetate has been applied
to every cell and system, including vascular smooth muscle to mimic the actions of DAG
78,79

Families of Protein kinase C
Molecular cloning reveals mammalian PKCs to be a family of at least 12 distinct
members. They can be subdivided into three subfamilies . The subfamilies of PKC are
classified on the basis of sequence similarities and their mode of activation:
1) The conventional or classic PKCs (oc,pl,p2, and y) are all activated by
phospholipid, in particular phosphatidylserine (PS), DAG and Ca+/.
2)

The novel or new PKCs (S, s, q, and 0) are all activated by phospholipid (PS)
and DAG but not by Ca+2.
+2

3) The atypical PKCs (A,,i,^, and p) require neither Ca nor DAG for activation but
are activated by PS.
Structural Components of Protein kinase C
The isoforms PKC-a, -pi, -p2, -5, -s, and

have been reported in vascular

smooth muscle; however their role in modulating contraction is not well defined. All the
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PKCs have a common catalytic domain, comprised of two highly conserved subdomains.
C3 and C4. They all contain a cysteine-rich region, C1, and, in addition, the conventional
•

•

-4-9

and novel PKCs contain the C2 domains that bind Ca . They are all characterized by the
presence of a pseudosubstrate sequence that plays a role in maintaining the kinase
inactive in the absence of a stimulus (Figure 14)

Pseudo

phorbol ester
zinc

substrate

80,81

PS
substrate

ATP

Ca+2

C2

C3

PUP

regulatory

I

C4
catalytic

hinge
Figure 14: Conventional structural domain and activation of protein kinase C

C1-C4 regions of Protein Kinase C
The amino acid sequence reveals four conserved functional domains, C1-C4.
Proceeding from the N-terminus, Cl and C2 constitute the regulatory domains, and then
C3 and C4 together constitute the catalytic domain characteristic in all kinases. The
regulatory and the catalytic domains are linked by a hinge region. C1 contains a cysteinhistidine-rich motif ("zing finger’) that coordinates Zn atoms. This forms the binding site
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i

for DAG and phorbol esters. The C2 domain binds negatively charged phospholipid,
such as phosphatidyl serine (PS), a phospholipid and Ca+2 . In the segment immediately
N-terminal to the Cl domain is a stretch of amino acids (19-36 in PKCa), which
constitutes the autoinhibitory pseudosubstrate. Its sequence resembles the consensus
phosphorylation sites present in target proteins that are phosphorylated by PKC. In the
absence of a stimulus, the catalytic domain binds to the pseudosubstrate, causing the
enzyme to fold about the hinge linking C2 and C3. This results in the suppression of the
kinase activity .
Summary of Protein kinase C Involvement in Vascular Smooth Muscle
Protein kinase C is an enzyme that activates various cells downstream.
particularly vascular smooth muscle cells. PKC has been linked to adrenergic (oci), and
to angiotensinergic (ATj) receptor activation coupled to phospholipase C and
phospholipase D. It is not clear how important a role PKC plays during the sustained
+2

phase of smooth muscle contraction, when the influence of Ca

is limited. There are

more questions than answers in regards to PKC activation due to the stimulation of PHE
and Ang II induced tension development in the rat-tail.
In view of the fact that DAG is a requirement for the activation of PKC in the
regulation of vascular smooth muscle contraction, the regulation of PKC is clearly linked
to the activation of PTC and PLD indirectly. Figure 15 summarizes the pharmacomechanical coupling events: Both adrenergic and angiotensinergic receptors are coupled
to a heterotrimeric G-protein, Gaq/npyand Ga^Pyrespectively. Then, the G-proteins
activate a specific effector, PLCpl and PLD1 respectively. During the early phase of
smooth muscle contraction, PLCpl hydrolyses PIP2 to release IP3 and DAG; IP3 moves
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from the membrane to the cytosol and binds to the IP3 receptor located on the surface of
the SR, which results in the release of Ca+2. Then 4 Ca+2 ions bind to calmodulin to
create a complex that binds to MLCK. This complex phosphorylates the myosin head.
resulting in the interaction with actin. Tension or contraction in vascular smooth muscle
-f9

develops. Meanwhile, DAG and Ca interact near the plasma membrane to activate
PKC. PKC has many cellular effects. One of the many hypotheses is that the active PKC
relocates from the membrane to the cytosol to phosphorylate CPI-17, a myosin light
chain phosphatase (MLCP) inhibitor. The active phosphorylated CPI-17 inhibits the
MLCP, so that MLCK activity is potentiated. As a result, the vascular smooth muscle
prolongs its cross-bridge formation during the late phase of contraction. In regards to
PLD1, PKC’s role in its activation is known, but whether this potentiation is working
through the AT 1 receptor pathway is uncertain.
Our objectives in this project are to:
1) Determine the effect of PKC in the contractile response to PHE and Ang II in the
rat-tail artery. What role if any does protein kinase C play in response to PHE
and Ang II response in the rat-tail artery? Is the activation of protein kinase (J
during the early or late phase of smooth muscle contraction?
2) Determine the effects of phenylephrine (a 1-adrenergic agonist), angiotensin II
(AT] agonist), clonidine (ct2-adrenergic agonist) and moxondine (a2-adrenergic
/Ii agonist) on the rat-tail. Which receptor response is more or less dominant in
the rat-tail? Is moxonidine a true 0L2 agonist? Does Mox show Imidazoline (f) or
oti- or a2-adrenergic agonist characteristics in the rat-tail?
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Figure 15: Summary of adrenergic and angiotensinergic coupled contraction in vascular
smooth muscle. Components: PLC, phospholipase C; PLD, phospholipase D, IP3,
inositol trisphosphate;PA, phosphatidic acid; PKC, protein kinase C; DAG,
diacylglycerol; MLCK, myosin light chain kinase; MLCP, myosin light chain
phosphatase.
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CHAPTER THREE
MATERIALS AND METHODS
Experimental Animals
Male adult Sprague-Dawley rats (200-300g) were killed by decapitation. The
proximal tail arteries were removed and placed in Krebs physiological solution (KPS)
containing (in mM) - 118 NaCl, 5.4 KC1, 2.5CaCl2, 12.5 NaHC03, 1.12MgS04, 1.2
KH2PO4, and 10 glucose. The final pH was 7.4. The Krebs solution was bubbled
continuously with 95% 02-5 % CO2.
Isolation of Proximal Rat Tail Artery
Ring segments 5 mm in length were cut from the rat-tail artery. Two platinum
wires were inserted into the lumen of the segment for mounting on the force transducer
apparatus. The mounted vessels were immersed in 6 ml tissue bath of KPS at 37°C
equilibrated with 95%02-5%C02- After the vessel segments were mounted in the tissue
baths, they were allowed to equilibrate for 60 minutes with KPS changes every 15-20
minutes (Figure 16). After 60 minutes, passive tension was slowly applied over 30
minutes to each vessel in the bath in the range of 1.0-1.2 g so that an optimal contractile
response was elicited. Care was taken not to overstretch the vessels 87 .
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Figure 16: Sketch of the experimental set-up for arterial ring fixation. Two triangle
platinum wires are inserted into the lumen of a 5 mm rat-tail artery. The segments are
placed on a strain gauge. The mounted vessels are immersed in 6 ml tissue bath of Krebs
solution at 37° C equilibrated with 95%02-5%C02. Radius of the artery is changed with
an adjustable micrometer. Krebs solution is insulated in a bath with water flowing in and
out with the help of temperature regulated coil water pump.
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Removal of the Endothelium
To avoid the complications of endothelial-mediated effect, we removed the
endothelium by carefully inserting a small wire three times into the lumen of the vessels.
After equilibration, the tissue viability was determined by the contractile response to 10
pM phenylephrine (PHE). The absence of a relaxation response to acetylcholine (10 pM )
was evidence that the vessel segments were functionally denuded of endothelium 88.
After completing the test on the endothelium, the vessels were used immediately for the
experiments.
Dose Response Relationships
Dose-response relationships for vascular smooth muscle (VSM) contraction was
determined using various agents in order to find their maximum contraction. VSM was
activated pharmacologically, with potassium chloride (KC1), phenylephrine (PHE),
angiotensin II (Ang II), moxonidine (Mox), and clonidine (Cion). Increasing doses of the
agonist were given in logarithmic steps and maximal contraction of the vessel segments
were measured in grams of developed tension (g). The bath was rinsed twice with Krebs
solution and 15 min were allowed for tissue equilibration before proceeding to the next
stimulus. Concentration of agonist that gave 50% of maximum response (EC50) and
maximum contractile response (Emax) was determined from our dose-response curves, and
used in future experiments. We chose these maximal levels since it elicited consistent
responses.
Pharmacological Antagonist Studies
After completion of the dose response studies, antagonist studies were conducted
to verify adrenergic and angiotensinergic receptor activity. The effects of PKC inhibitors
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(calphostin C and chelerythrine chloride) on the contractile response to agonists were
tested. Vessels were pretreated for 15 min with either calphostin C (10 nM tolOO nM) or
chelerythrine (10 nM to 10 pM), followed by treatment with PHE (10 pM) or Ang II (10
pM).

Also tested were the effects of

-adrenergic antagonist (prazosin and urapidil)

on the contractile response to agonists. Vessels were pretreated for 10 min with either
prazosin or urapidil, followed by 5 min treatment with PE (1 pM) or moxonidine (IpM).
In addition, vessels were also pretreated with efaraxon (imidazoline/a2-adrenergic
antagonist), yohimbine (a2-adrenergic specific antagonist) or U73122
(phosphatidyinositol-phospholipase C inhibitor) for 10 min, followed by 5 min treatment
with moxonidine or PHE.
Preparation of Rat Tail Artery Vascular Smooth Muscle Cells
Proximal rat-tail artery vascular smooth muscle cells were prepared by enzymatic
dissociation as previously described 90. The 10 mm ring segments taken from rat-tail
artery were placed in a sterilized physiological Krebs solution. The Krebs solution was
vacuum filtered in a 250 ml filter system filled with .22 pm cellulose acetate (ca)
sterilizing, low protein binding membrane from Sigma Chemical. The ring segments
were washed three times in the Krebs solution. After the third wash, the arterial
segments were minced into pieces, and placed in a tissue culture dish with the enzymatic
digestion solution prepared as described by Apkon 90.

The sterilized digestion solution

contained 2 pg/ml deoxyribonuclease, 0.5 mg/ml collagenase of type II, soybean trypsin
inhibitor 0.25 mg/ml, elastase 55 pl/ml, and Antibiotic Antimycotic Solution-100X 36.5
pl/ml. All enzymes and solutions were obtained from Sigma (St. Louis, MO). pH was
adjusted with a few drops of 0.1 N NaHCOa solutions before the dissociation. The tissue
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suspensions were incubated at 37°C for 45-60 min with constant superfusion with a 95%
air-5 % CO2 gas mixture. During this incubation period, the tissue suspensions were
vortexed for 1 minute at each 15 min interval until the 60 min incubation was completed.
Enzymatic digestion was slowed down with 5 ml of tissue culture medium
[Dulbecco’s Modified Eagle’s Medium (DMEM)] supplemented with 15 % fetal calf
serum. After termination of digestion, the debris of cells and tissue were incubated
overnight at 37° C for 15-17 hr with constant superfusion of 95% air-5 % CO2 gas
mixture. The following day, the debris of cells and tissue were scraped from the tissue
culture dish, and additional DMEM was added (4 ml). The debris was centrifuged at 200
g for 5 minutes. Afterwards, the supernatant fluid was removed, and 1 ml of DMEM
was added to the cells. The mixed medium containing the cells was transferred to a 25
cm2 canted neck flask to be plated. The flask was incubated overnight at 37° C
superfused with a 95% air-5% CO2 gas mixture. After 2-3 days cells were 40% confluent.
Microscopically (10X) identified as smooth muscle by their spindle-shape.
To insure further that these were smooth muscle, their alpha actin was immunohistochemically marked with primary antibody (mouse monoclonal anti-cc-smooth
muscle actin) and biotinylated secondary antibody (goat anti-mouse immunoglobulin in
buffered saline). Positive test would show the smooth muscle cell nuclei to be blue,
while the cytoplasm was stained rose-red to brownish-red 90. Within approximately 2
weeks, the cells were observed to form confluent islands of cells on the culture flask.
A7r5 and Primary Vascular Smooth Muscle Cell Fixation
A7r5 vascular smooth muscle cells were obtained from American Type Culture
Collection (Manassas, VA) and maintained in culture for 5-10 passages. Cells were
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grown to confluence under 95% air-5% CO2 gas mixture at 96% humidity and 37°C in
Dulbecco’s modified Eagle’s medium (DMEM). The medium contained 15% fetal
bovine serum and 1.5% antibiotic antimycotic solution-100X. The medium was changed
every 5 days. Every 2 weeks, confluent cell layers were passaged by treatment for 8 min
with sterile filtered trypsin IX solution (Sigma Chemical Co.). Cells were vigorously
shaken 5-8 times from the bottom of the flask, resuspended in the growth medium.
diluted, centrifuged at 200 rpm for 5 minutes, and re-plated in 10 ml of DME medium.
A7r5 cells and primary cells were fixed as previously described

90,93

. Both cells

were fixed on a 20 mm sq. Coming cover glass placed in a 60 mm tissue culture dish.
Before fixation, the culture dish and cover glass slips were twice washed in 2 ml of
antibiotic antimycotic solution-100X (Sigma Chemical Co.).

Three ml of DME medium

was then added separately to the culture dish with A7r5 cells and primary cells for
attachment. After 48 hours of incubation under 95% air-5% CO2 gas mixture and 96%
humidity at 37° C, cells were attached to the cover glass and developed morphologically
for immunohistochemistry study. Thereafter, the cover glass was removed from the
culture dish and placed on a microscope slide. Histological mounting medium was used
to fix the cover slip over the slide. After about 10-15 min the slides were ready for cell
tissue fixation similar to the protocol provided by Sigma.
Immunohistochemistry Study of Vascular Smooth Muscle Cells
A7r5 and primary cells were fixed on slides and placed in Bouin’s Solution
(Sigma Diagnostics) for 18 hours. Afterwards the slides were immersed in protease
(lOOmg/lOOml) and placed in the incubator at 37°C- 96% humidity for 30 minutes. One
phosphate buffered, saline tablet was dissolved in 200 ml of nanopure water to obtain: 10
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mM phosphate buffer, 2.7 mM NaCl and 137 mM NaCl, pH 7.4 at 25°C. This saline
solution was used to rinse the slides throughout the immuohistochemistry study. After
the 30 min incubation with the 0.1% protease, 2 drops of 3% hydrogen peroxide was
added to the fixation and left at 25°C for 5 minutes. The slide was washed and wiped
dry. Blocking reagent (normal goat serum) was then added and left for 15 minutes. Then
2 drops of primary antibody or negative control (normal mouse serum) was added and
left for 60 minutes. The slide was washed and wiped dry. Two drops or 50 pi of
biotinylated secondary antibody was added and left for 20 minutes. The slide was
washed and wiped dry. Thereafter, 2 drops of peroxidase reagent was added to the slide
and left for 20 minutes. The slide was washed and wiped dry. Two drops of substrate
reagent containing 4 ml of nanopure deionized water, 2 drops of acetate buffer, 1 drop of
AEC Chromogen and Idrop of 3% hydrogen peroxide, were added to the slide and left
for 15-20 minutes. After sufficient staining had been achieved, the slide was washed for
5 minutes in nanopure-deionized water. Afterwards, the slide was counterstained with
Mayer’s hematoxylin for 4 minutes. The slide was rinsed then over gently running tap
water to “blue” the hematoxylin. Finally, glycerol gelatin was applied on the slide and a
cover slip was placed over it to observe the fixed cells at XI0 or X40 magnification on a
microscope 90,91
Preparation and treatment of the artery for Thin Layer Chromatography
Tail artery segments were immersed in 6 ml tissue bath of HEPES (5 mM)buffered Krebs physiological solution (HKPS) at 37° C equilibrated with 95% air-5%
CO2 for 60 min. The segments were then transferred to tubes containing [ H] myristic
acid (50 pCi/0.5 ml) in HKPS, 1% serum albumin. The incubation continued for another
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180 min. Segments were washed twice quickly in 5 ml buffer, and then incubated in 1ml
buffer for 30 min. The segments were washed three times (3X). Afterwards, the
segments were incubated with specific concentrations of stimuli for 10 min. Group 1:
buffer alone; Group 2: Ang II alone; Group 3: 2% ethanol alone; Group 4: ethanol (2%)
+ Ang II (10M). Afterwards all the groups were placed in dry ice. The segments were
frozen and saved for the extraction and measurement of membrane lipids

92,93

Measurement of membrane lipids in rat-tail artery
Membrane lipid extraction was performed according to the methods given by
LaBelle and Murray

. The segments were frozen in a mortar immersed in liquid N2 (to

which 0.4 ml 2.4 M HC1 had been added). The frozen samples together with the frozen
acid solution were homogenized to powder with a chilled pestle for 3 min, and then
allowed to thaw for 5 min. The powder was treated with 1.5 ml cold (0°C) chloroformmethanol (1:2) and the resulting one-phase liquid transferred to a cold glass tube. The
mortars were rinsed with 3 ml chlorform-methanol, and the rinses were combined with
the initial extracts. The combined extracts were treated with 2.3 ml HC1 (2.4 M) and 1.5
ml chloroform. The resulting two phase mixture was clarified by centrifugation for 5 min
at 1,000 g. The chloroform phases were transferred to clean tubes, and the aqueous
phases were washed with 2 ml chloroform. The combined chloroform phases were
washed with 0.4 ml HC1 and 3 ml methanol-water (1:1). The chloroform phases were
dried under nitrogen and the dried lipids dissolved in 100 pi chloroform and spotted on
thin layer plates (Linear K5 (150 A) Whatman) along with the standard phospholipids
(phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid). The TLC plates
(Fisher Scientific) with fluorescent indicator provide choice of high purity silica gels and
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polarity for normal phase separation. They were then developed with chloroformmethanol-4 M ammonium hydroxide (90-70-20:v-v-v). The developed thin layer plates
were observed under UV light. Spots were marked and then scraped in to 5 ml
scintillation vials. Scintillation fluid was added, and then the samples were counted in a
liquid scintillation counter (Beckman)

.

Drugs and Chemicals
Angiotensin II, acetylcholine, phenylephrine, clonidine, yohimbine, U73122,
prazosin, urapidil, and ingredients for Na and K Krebs and HEPES were obtained from
Sigma (St. Louis, MO USA). Chelerythrine chloride, calphostin C and efaroxan were
purchased from BIOMOL Research Labs, Inc (Plymouth Meeting, PA USA).
Moxonidine was a gift given by Dr. P. Emsberger from Case Western University, School
of Medicine, Cleveland, Ohio USA. All the drugs and chemicals were dissolved in
nanopure water.
Determination ofpA2 values
A competitive antagonist binds reversibly to the same receptor as the agonist. A
dose-response curve performed in the presence of a fixed concentration of antagonist will
be shifted to the right, with the same maximum response and generally the same shape.
Using the Furchgott equation: [A]b/[A] = 1+[B]/Kb where [A] is the agonist
concentration in the absence of the antagonist (control tissue) and [A]b is the agonist
concentrations in the presence of antagonist at the pD2 (measure of the agonist affinity).
[B] is concentration of the competitive antagonist, and Kb is the antagonist dissociation.
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pA2 is a true measure of antagonist affinity and is connected to Kb by the equation: pA2
-logio Kb. A plot of Log [A]b/[A] (dose ratio) against log [B] gives a straight line of
intercept KbStatistical analysis
All values were calculated as means ± SE. In all cases, N values refer to the
number of rats used in each experiment. When appropriate, we used multiple range test
with the ANOVA to look at the differences between the means. P value of <0.05 was
considered significant. GraphPad InStat and Prism 3.0 computer software were used for
statistical analysis for all data values.
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Table 2: Structure of Agonists and Antagonists used in the Experiments
Compounds
Phenylephrine

Function
ai-selective
adrenergic
receptor agonist

Structures or Formulas
OH
HO.

ch—ch2—nhch3

/Cl

Clonidine

ct2-selective
adrenergic
receptor agonist

N
H
Cl

Moxonidine

Ii/a2-selective
adrenergic
receptor agonist

Efaroxan

Ii/a2-selective
adrenergic
receptor
antagonist

Yohimbine

ot2-selective
adrenergic
receptor
antagonist

N
N

COOH3C
OH

a 1-selective
adrenergic
receptor
antagonist

Prazosin
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ai-selective
adrenergic
receptor
antagonist

Urapidil

U73122

Angiotensin II

Phosphatidylinositol specific
phospholipase C
inhibitor
AT] receptor
agonist

C29H40N2O3

C5oH71N13012

OH

chgO

Calphostin C

0

S

Cl
-C-

%

0CH3 6

OH

0
Calphostin C

OH

Highly specific
inhibitor of PKC
that interacts with
the protein’s
regulatory
domain by
competing at the
binding site for
diacylglycerol
and phorbol
esters. Does not
compete with
Ca+2 or
phospholipids.

Potent and
selective inhibitor
of PKC Acts on
the catalytic
domain of protein
kinase C.

Chelerythrine
chloride

OCH3
Chelerythrine chloride
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CHAPTER FOUR
RESULTS
The goal of my project was to distinguish clearly the oti and ATj receptor
activation in the proximal rat-tail artery. Phenylephrine (PHE) was tested on the tissue to
determine dose response relationships and to quantitate adrenergic receptor activation.
As concentration or the strength of stimulus was increased, the developed tension
increased in a dose dependent manner (Figure 17). The EC5o = 1 pM and tension at 50%
concentration was 1.39 g. The E

i\

10 pM and tension at 100 % concentration was 2.69

gFigure 18, illustrates the response of the tail artery to angiotensin II (Ang II). As
concentration of Ang II was increased, the developed tension increased in a dose
dependent manner. The ECso^O.l pM and tension at 50% concentration was 0.331 g.
The Emax=10 pM and tension at 100 % concentration was 0.482 g.
Figure 19 shows a comparison of the dose response relationships between PHE
and Ang II induced tension development in the rat-tail. We conducted this experiment to
compare the efficacy and potency of the two drugs in the tissue. We wanted to validate
the presence of adrenergic and angiotensinergic receptors in the tail artery. PHE response
was greater than the Ang II response, and it increased with concentration up to the
maximum. Both curves showed saturation.
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Figure 17: Dose-response relationship for PHE-induced tension development in rat-tail
artery. All values are indicated as means ±SE of six experiments (N=6). EC50=1 pM and
Emax=l°HM-
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Figure 18: Dose-response relationship for Ang II induced tension development in rat-tail
artery.Tissue was treated as described in material and methods. Ail values are indicated
as means ±SE of five experiments (N=5). EC50=0.1 pM and Emax^l 0 pM.
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Dose response relationships of PHE and Ang II were compared to potassium.
This experiment was conducted to normalize all the data. Figure 20 shows the contractile
response of PHE and Ang II as a percent maximum KC1 contractile response. PHE
response was greater than the Ang II response, and it increased with concentration up to
the maximum, both curves showed saturation.
Time-tension relationship for PHE and Ang II were determined to elucidate early
and late phase development of contraction between adrenergic and angiotensinergic
receptor activation in the rat-tail. Figure 21 shows time related development of tension
between PHE and Ang II from 0 to 5 minutes (0 to 300 seconds). As can be seen, PHE
produced a greater and faster contraction (2.6 g maximum tension, t5o=12 sec) than Ang
II (0.5 g maximum tension, t5o= 43 sec). T50 represents the time it takes for a ligand to
develop 50% maximum tension.
After determining the dose response relationship between PHE and Ang II, and
establishing EC50 and Emax doses, we wanted to investigate the influence of protein kinase
C (PKC) on both receptor pathways. Calphostin C was determined to be a highly specific
PKC inhibitor that interacts with the protein’s regulatory domain by competing at the
binding site for DAG and phorbol esters. Figure 22A shows PHE, aj-adrenergic agonist.
stimulation resulted in no significant dose dependent inhibition in the presence of
calphostin C (10 nM, 50 nM, and 100 nM).

Whereas, Figure 22B shows Ang II (ATj

agonist), stimulation resulted in dose-dependent inhibition in the presence of calphostin
C. The concentration of the drug that produced 50% inhibition (IC50) was determined to
be 100 nM.
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Figure 19: Comparison of dose-response relationship for PHE and Ang II induced tension
development in rat-tail artery. PHE response is greater than the Ang II response, and it
increases with concentration up to the maximum. Both curves show saturation. All values
are indicated as means ±SE of five experiments (N=5).
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PHE & Ang II Dose Response
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Figure 20: Comparison of dose-response relationship for PHE and Ang II induced tension
development in rat-tail artery to % maximum response to 106 mM potassium.
PHE response is greater than the Ang II response, and it increases with concentration up
to the maximum. Both curves show saturation. All values are indicated as means ±SE of
five experiments (EN5).
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Figure 21: Time-tension relationship for Ang II (10 pM)and PHE(10 pM)-induced
tension development in rat-tail artery. All values are indicated as means ±SE of seven
experiments (N=7). PHE produced a greater and faster contraction (2.6 g max tension,
t50=T2 sec) than Ang II (0.5 g max tension, t^^S sec).
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To further clarify the role of PKC in the oti and ATi receptor pathway, we used a
second inhibitor called chelerythrine chloride. This compound is structurally a different
compound from calphostin C. It is a potent and selective PKC inhibitor that acts on the
catalytic domain of PKC. As can be seen in Figure 23 A, PHE stimulation resulted in no
significant dose-dependent inhibition in the presence of chelerythrine from the 10 nM,
100 nM, 1 pM, and 10 pM range. Whereas, in Figure 23B, Ang II stimulation resulted in
a dose-dependent inhibition in the presence of chelerythrine (100 nM, 1 pM, and 10 pM
range). We determined the IC50 to be 1 pM for chelerythrine.
In order to differentiate the potency of the PKC inhibitors, we used calphostin C
(100 nM) and chelerythrine (10 pM) to determine which drug was more or less effective
in lowering PHE and Ang II induced tension in the rat-tail. Figures 24A and 24Bshows
that calphostin C and chelerythrine caused maximum inhibition via the Ang II induced
tension, but these PKC inhibitors did not attenuate the PHE induced tension at the same
concentrations. Also, chelerythrine was more potent than calphostin C.
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Effect of Calphostin C on PHE induced
tension in rat-tail artery
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Figure 22: (A) Phenylephrine, -agonist, stimulation resulted in no significant dosedependent inhibition in the presence of PKC inhibitor (10 nM to 100 nM). All values are
indicated as means ±SE of five experiments (N=5). (B) Whereas, Ang II, a AT, agonist,
stimulation resulted in a dose-dependent inhibition in the presence of Calphostin C
(IC5O=100 nM, P< 05, N=5).
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Effect of Chelerythrine on PHE induced tension in
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Figure 23: (A) PHE stimulation resulted in no significant dose-dependent inhibition in the
presence of PKC inhibitor from the 10 nM to 10 pM range. (B) Angiotensin II
stimulation resulted in a dose-dependent inhibition in the presence of PKC inhibitor.
Chelerythrine (IC50=1 pM) inhibited ATI receptor activity. The P value is <0.01 and is
highly significant from the 1 pM to 10 pM concentration when compared with the
agonist (Ang II). All values are indicated as means ±SE of five experiments (N=5).
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Figures 24A&B: Calphostin C and chelerythrine showed maximal inhibition via the Ang
II induced tension at the concentrations of 100 nM and 10 jiM respectively, but these
PKC inhibitors did not inhibit the PHE induced tension at the same concentrations. All
values are indicated as means ±SE of five experiments (N=5).
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After determining PKC involvement in angiotensinergic-coupled contraction in
the rat-tail artery, biochemical studies were conducted to elucidate the role of
phospholipase C (PLD). Figure 25 shows that Ang II in the presence of ethanol induced
over 3-fold increase in the production of PEt indicative of PLD activity. It also shows a
progressive increase in the production of PEt from the control, ethanol only, Ang II only.
and Ang II + ethanol study.

Effect of Ethanol on Ang II stimulated [ 3H]phosphatidylethanolamine release
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Figure 25: Production of phosphatidylethanol (PEt) provides direct evidence of PLD
activity. Segments of rat-tail artery were incubated with [3H] myristic acid (50 pCi/0.5
ml) and then phospholipids were extracted and separated by thin layer chromatography
and radioactivity was determined in a scintillation counter. Ang II in the presence of
ethanol induced over 3-fold increase in the production of PEt indicative of PLD activity.
All values are indicated as means ±SE of three experiments (N=3).
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To further clarify adrenergic activity in the rat-tail, clonidine (a,2-adrenergic
agonist) and moxonidine (a2-adrenergic agonist) were tested to establish dose response
relationship. In Figure 26, clonidine was tested on the tissue to determine dose response
relationships and to specify a.2-adrenergic receptor activation. As concentration was
increased, the developed tension increased in a dose dependent manner. The EC50 =0.6
pM and Emax = 1 mM. All data values were normalized to 106 mM % maximum K
response.
As can be seen in Figure 27, moxonidine was tested on the tissue to determine
dose response relationships. As concentration was increased, the developed tension
increased in a dose dependent manner. The £€50= 0.6pM and E max =:10mM. All data
values were normalized to 106 mM % maximum K+ response.
In order to determine if the drug moxonidine showed a 1-adrenergic characteristic.
dose response relationships were compared to PHE, a selective cti-adrenergic agonist in
the rat-tail tissue. Figure 28 shows no significant difference between the two drugs as
concentrations were increased, the developed tension increased in a dose dependent
manner. The EC50= 2.5 pM for PHE and Mox EC50= 1.3 pM. Pharmacologically, the
EC50 of both drugs are similar in the rat-tail, which imply activation of similar adrenergic
receptor coupled contraction.
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Figure 26: Dose-response relationship for Clonidine induced tension development in rattail artery. Tissue was treated as described in Material and Methods. All contractile
responses are expressed as % maximum responses to 106 mM K+. All values are
indicated as means ±SE of five experiments (N=5). EC50= 0.6 pM and Emax""" 1 mM.
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Moxonidine dose response
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Figurer 27: Dose-response relationship for moxonidine induced tension development in
rat-tail artery. Tissue was treated as described in Material and Methods. All contractile
responses are expressed as % maximum responses to 106 mM K+. All values are
indicated as means ±SE of seven experiments (N=7). EC50=T.3 pM and Emax=:10 mM.
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Figure 28: Comparison of dose-response relationship for phenylephrine (EC50=2.5 pM)
and moxonidine (EC50= 1.3 pM ) induced tension in rat-tail artery. Tissue was treated as
described in Material and Methods. All contractile responses are expressed as %
maximum responses to 106 mM potassium. Data are the mean ±SE for seven
experiments (N=7).
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To further elucidate the function of moxonidine, the drug was tested to identify an
a.2 adrenergic response. Pharmacological antagonist studies were conducted with
yohimbine (a2-adrenergic selective antagonist) and efaroxan (I^c^-adrenergic
antagonist). Mox concentration used in this experiment was 1 pM. Figure 29 shows that
both yohimbine and efaroxan attenuated the tension developed by Mox. IC50 represents
the inhibitory concentration of 50 % response. Yohimbine IC50= 35 nM and efaroxan
IC30= 49 nM. This data suggest that moxonidine shows (X2 adrenergic response.

Effect of Efaroxan and Yohimbine on
Moxonidine induced tension in rat-tail artery
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Figure 29: Effect of I,/a2 antagonist efaroxan (IC50=49 nM), and a2-selective antagonist
yohimbine (IC50= 35 nM) on moxonidine induced tension in rat-tail artery. Tissue was
treated as described in Material and Methods. All contractile responses are expressed as
% maximum responses to 106 mM potassium. Data are the mean ±SE for five
experiments (N=5).
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We further conducted pharmacological antagonist studies to determine if
moxonidine does show a]-adrenergic response in the rat-tail. The response of Mox was
compared with PHE in the presence of prazosin and urapidil, both a i-adrenergic
antagonists.

Figure 30 shows that both PHE and Mox induced tension in rat-tail artery

was attenuated in the presence of prazosin in a dose dependent manner.

The data shows

the drug moxonidine being inhibited by a specific ai-adrenergic antagonist.
Similarily, the response to PHE and Mox induced tension were tested at a higher
concentration to identity cci-adrenergic response in the rat tail. Figure 31 shows that both
PHE (EC75HO pM) and Mox (£€75= 10 pM) induced tension in the rat-tail was
attenuated in the presence of prazosin in a dose dependent manner.
To further determine the possibility of an oti-adrenergic response, PHE and Mox
induced tension was tested in the presence of urapidil. This drug is a a,-adrenergic
selective antagonist that is structurally different from prazosin, but functions similarly.
Figure 32 shows that both PHE and Mox induced tension in the rat-tail were attenuated in
the presence of urapidil in a dose dependent manner.
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Effect of Prazosin on PHE and Mox
induced tension in rat-tail artery
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Figure 30: Effect of dj-selective antagonist prazosin, on Mox (EC50=1 pM) and PHE
(EC50=1 pM) induced tension. Tissue was treated as described in Material and Methods.
Responses to prazosin IC50=:1 nM in the presence of moxonidine (1 pM) and IC50=2 nM
in the presence of phenylephrine (1 pM). All contractile responses are expressed as %
maximum responses to 106 mM K+. Data are the mean ±SE for seven experiments
(N=7).
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Effect of Prazosin on Mox and PHE
induced tension in rat-tail artery
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Figure 31: Effect of a,-selective antagonist prazosin, on moxonidine (EC75=10 pM) and
phenylephrine(EC75=10 pM) induced tension. Tissue was treated as described in
Material and Methods. Responses to prazosin IC50= 3 nM in the presence of moxonidine
(10 pM) and IC50=3 nM in the presence of phenylephrine (10 pM) are shown. All
contractile responses are expressed as % maximum responses to 106 mM K+. Data are
the mean ±SE for seven experiments (N=7).
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Effect of Urapidil on PHE & Mox
induced tension in rat-tail artery
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Figure 32: Effect of o^-selective antagonist urapidil on moxonidine (EC50=1 pM) and
phenylephrine (EC50=1 pM) induced tension. Tissue was treated as described in Material
and Methods. Urapidil IC50=:14 nM in the presence of moxonidine (1 pM) and IC50=8
nM in the presence of phenylephrine (1 pM). All contractile responses are expressed as %
maximum responses to 106 mM K+. Data are the mean ±SE for six experiments (N=6).
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To further determine if Mox is working through cti-adrenergic receptor in the rattail artery, we conducted a pharmacological comparison study between the oti- and ot2adrenergic antagonists. Figure 33 shows that yohimbine, prazosin, and urapidil alone
attenuated mox induced tension in the rat-tail. For cti receptors, the rank order of potency
is: prazosin > urapidil > yohimbine. Clearly, a combination of yohimbine and prazosin
inhibited mox response by > 50%. In addition, combination of yohimbine, prazosin and
urapidil almost completely attenuated mox induced tension in the rat-tail artery.

Effect of Yohimbine, Urapidil and Prazosin on Moxonidine induced tenion in rat-tail artery
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Figure 33: Effect of a,-selective adrenergic antagonists urapidil[U] (10 nM) and
prazosin[P] (10 nM), and a2-selective adrenergic antagonist yohimbine [Y](10 nM), on
moxonidine induced tension. All contractile responses are expressed as % maximum
responses to 106 mM K+. Data are the mean ±SE for five experiments (N=5),
*P < 0.0001 for Y+U+P (lOnM).

To further explore the involvement of aj-adrenergic receptors in moxonidine
effect on rat-tail artery, we decided to conduct competition experiments. This approach
has been widely adopted by the pharmaceutical industry as a rapid means of determining
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the affinity of new drugs or compounds for a particular receptor for which a wellcharacterized drug is available. Figures 34 and 35 shows concentration dose response
curves for both PHE and Mox in the presence of three separate doses of prazosin (1 nM,
10 nM, and 100 nM). With increasing concentration of antagonist, prazosin, curves for
PHE and Mox showed classical right-shift, causing the drugs to behave as if it were less
potent (competitive inhibition). Using the Furchgott equation described in Material and
Methods, we determined the pA2 for PHE and Mox, 10.2 and 9.35, respectively. pA2 is a
true measure of antagonist affinity.
Time-tension relationship for PFIE, Mox, Cion were determined to elucidate early
and late phase development of contraction in the rat-tail between the known adrenergic
agonist. All three agonists were compared to K+ response. Figure 36 shows time related
development of tension between K+, PHE, Mox and Cion from 0 to 5 minutes or (0 to
300 seconds). K+ produced a greater and faster contraction than PHE, Mox, and
Clonidine. Table 3 shows a comparison of the various factors involved in time tension
relationship.
Agonist

Initial Rate (g sec'1)

T5o (sec)

Max tension (g)

K+

.147

11

4.5

PHE

.147

12

2.6

Mox

.0317

41.25

2.6

Cion

.0317

37.5

2.3

Table 3: Factors describing the time tension relationship for KC1, phenylephrine,
moxonidine and clonidine.
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Phenylephrine response in rat-tail artery
120-,
8 100c
o

■

♦ Prazosin (1nM)
▼ Prazosin (10nM)
Prazosin (100nM)

8- 8°0

a:

^

PHE

60-

x

(TJ

S

40-

p

O

200
-9

T

T

T

T

T

T

T

1

-8

-7

-6

-5

-4

-3

-2

-1

log [PHE]

Figure 34: Effect of various concentrations of prazosin on phenylephrine induced tension
in rat-tail artery. Tissue was treated as described in Material and Methods. Phe EC50=2.5
pM (effective concentration for 50 percent response). Phe EC50=20 pM in the presence of
InM prazosin. Phe EC50= 76pM in the presence of lOnM prazosin. Phe EC50=508 pM
in the presence of 100 nM prazosin. All contractile responses are expressed as %
maximum responses to 106 mM potassium. Data are the mean ±SE for five experiments
(N=5).
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Moxonidine response in rat-tail artery
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Figure 35: Effect of various concentrations of prazosin on moxonidine induced tension in
rat-tail artery. Tissue was treated as described in Material and Methods. Mox EC^l .2
pM, Mox EC50=3.1 pM in the presence of 1 nM prazosin. Mox EC50=60 pM in the
presence of 10 nM prazosin. Mox EC50=961 pM in the presence of 100 nM prazosin.
All contractile responses are expressed as % maximum responses to 106 mM potassium.
Data are the mean ±SE for seven experiments (N=7).
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Figure 36: Time-tension relationship for K+ (106 mM), PHE (10 pM), Mox (10 pM), and
Clonidine (10 pM)-induced tension development in rat-tail artery. (N=7). KC produced a
greater and faster contraction than PHE, Mox, and Clonidine. Kf (4.5 g max tension,
initial rate= .147 g/sec, t5o= 11 sec), PHE (2.6 g max tension, initial rate = .147 g/sec,
t50=12 sec), Mox (2.6 g max tension, initial rate= 0.0317 g/sec, t5o= 41.25 sec ) and
Clonidine(2.3 g max tension, initial rate= .0317 g/sec, t50= 37.5 sec). All values are
indicated as means ± SE of seven experiments (N^T).
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In order to determine if moxonidine activates effector proteins like PLC, we
decided to use U73122, a selective Pi-phospholipase C antagonist. Figures 37 and 38
shows that both PFIE and Mox induced tension were attenuated in the presence of
U73122.

The data shows that both PHE and Mox developed tension via «i-adrenergic

receptors coupled to PLC in the rat-tail artery.

Effect of U73122 on PHE induced
tension in rat-tail artery
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Figure 37: Effect of a specific Phosphatidylinositol-phospholipase C inhibitor, U73122
on phenylephrine induced tension in the rat-tail artery. All contractile responses are
expressed as % maximum responses to 106 mM potassium. Data are the mean and ±SE
for four experiments (N=4), and vertical error bars indicate SEs for the number of
animals. The P value is < 0.001, considered significant (U73122, 10 pM) in the
inhibition of PHE induced tension on the rat-tail artery.
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Effect of U73122 on Mox induced
tension in rat-tail artery
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Figure 38: Effect of a specific phosphatidylinositol-phospholipase C inhibitor, U73122
on moxonidine induced tension in the rat-tail artery. All contractile responses are
expressed as % maximum responses to 106 mM potassium. Data are the mean and ±SE
for four experiments (N=4), and vertical error bars indicate SEs for the number of
animals. Moxonidine induced tension was attenuated significantly in the presence of
U73122 (10-50 pM). The P value is < 0.001, considered significant.
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CHAPTER FIVE
DISCUSSION
Pharmacodynamics involves the study of the biochemical and physiological
effects of drugs and their mechanism of action. A large percent of tail artery is smooth
muscle, and it is easier to correlate a biochemical event with force development in
smooth muscle. This is difficult to do with cultured cells. Our objective in this project
was to compare the effects of agonists for the ATj , oti, 0C2, and imidazoline receptors on
contraction in the rat-tail artery. Functionally, agonist at different receptors cause
contraction, but biochemically there are differences in how the result is achieved.
Further, we wanted to determine the role of protein kinase C (PKC) in the functional
regulation between ATi and a 1-adrenergic receptor pathways. We also wanted to clarify
adrenergic and angiotensinergic activation caused by the various agonists, and compare
and contrasts their effects with a known antagonists. In addition, we were interested in
elucidating the effects of moxonidine on the rat-tail. How does the moxonidine response
compare with known (X2 and a 1-adrenergic receptor agonists, clonidine and
phenylephrine, respectively?
In the first section of our study, we have shown pharmacologically that
phenylephrine (PHE, oti. adrenergic agonist) and angiotensin II (Ang II, ATi agonist)
caused contraction in the rat-tail artery. This validates the work of Cheung and Triggle
who gave pharmacological evidence for the existence of oti and ct2-adrenoreceptor sites
in the rat-tail artery

97,98

. Also, we found that PHE is more potent than Ang II when

compared to the normalized % K response. In fact, the response increases with
concentration up to a maximum, for Ang II (-20%) and PHE (-75%), respectively. Ang
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II causes vasoconstriction by direct stimulation of Ang II receptors (ATi) on smooth
muscle cells 94,95 . Our raw data numbers in regards to Ang II response were similar to
the published numbers by Jiang and Triggle96. The distribution of AT i receptors has
been studied extensively in the rat. Comparative studies have been performed using
classical binding techniques and displacements with ATj-and AT2- specific analogs. In
the last few years, mRNA expression studies have revealed that AT 1 receptors are
expressed in most all the physiological target organs of Ang II. They are expressed
exclusively in the lungs, liver, urinary tract, placenta and pituitary and are the principle
receptors in the kidney, adrenal cortex and heart 65.
It is now generally accepted that inositol trisphosphosphate (IP3) induced
intracellular calcium release is responsible for the rapid, transient increase in calcium
concentration observed in cells in response to Ang II. In the case of smooth muscle, this
initial IPi-mediated release of sequestered intracellular calcium leads to the activation of
a calmodulin-dependent protein kinase that phosphorylates light chain myosin, leading to
smooth muscle contraction. However, the mechanism by which Ang II causes a
sustained smooth muscle contraction remains unclear. We show in our time tension data
that Ang II induced maximum tension in the rat-tail is five times lower than the response
to PHE. This suggests, in the rat-tail, the number of AT 1 receptors activated by Ang II is
lower in comparison to the number of aj-adrenergic receptors activated by PHE. In
addition, contraction in response to Ang II develops in a sustained manner over five
minutes (Fig. 21), whereas with PHE response reaches a plateau by two minutes. In
contrast to the rapid, transient increase in IP3 formation, Ang II induces a biphasic
increase in diacylglycerol (DAG) formation, with an initial peak occurring at

94

approximately 15 sec and a second increase at approximately 5 min

109,110

. While it is

well established that the initial peak in DAG results from the action of phospholipase C
on PIP2, the origin of the second, sustained peak of DAG formation was unknown until
recently. However, it is now evident that Ang II can stimulate the hydrolysis of
phosphatidylcholine by both phospholipase C (PLC) and phospholipase D (PLD),
yielding DAG and phosphatidic acid (PA), respectively

111,112

Based on the biphasic nature of the inositol-signaling pathway, models have been
proposed to explain the biological action of adrenergic and angiotensinergic coupled
contraction of vascular smooth muscle. It has been suggested that the transient increase
in IP3 and intracellular calcium mobilization initiates and determines the magnitude of the
cellular response, while the sustained increase in extracellular calcium influx and DAG
formation leads to a continual activation of PKC, which is largely responsible for the
sustained portion of the vascular contraction

111,112

. Most of the work done in regards to

PKC involvement in slow, sustained contraction has been conducted in isolated rabbit
arteries'10, cerebral and renal arteries, spontaneously hypertensive rats121, and vascular
cell lines like Ayrs and primary cells from the kidney and heart 92,120,122 . Not much work
has been conducted in Sprague-Dawley rat-tail arteries.
The first evidence that PKC was involved in PLD activation derived from the
observation that phorbol esters increased PLD activity. In cell-free systems, using
recombinant PKC isoforms and membranes derived from human neutrophils, the
conventional PKC significantly upregulated PLD activity 113. Sciorra et al.,114 showed
that calphostin C downregulated PLD activity, implying PKC involvement in the
regulation of PLD activity in SF-9 insect cells. Weber et al.,U5 used the rat-tail artery to
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investigate the involvement of PKC in myosin phosphorylation and force development.
They found that inhibition of PKC by chelerythrine or calphostin C had no significant
effect on resting [Ca+2]j or increase in [Ca+2]j evoked by cirazoline (a i-adrenergic
agonist). Cirazoline induced contraction was much more sensitive to myosin light chain
kinase (MLCK) inhibitors (ML-9 and wortmannin), reconfirming the importance of
MLCK in phosphorylating myosin light chain that leads to smooth muscle contraction 116.
In our study, we used PHE rather than cirazoline, and compared the effect of calphostinC and chelerythrine with Ang II. We showed that both PKC inhibitors did not reduce ctr
adrenergic induced contraction. On the contrary, Ang II induced contraction was reduced
significantly by calphostin-C and chelerythrine. This suggests that Ang II induced
contraction in tail artery model may be working via PKC. Evidence in the literature
suggests that PHE induced tension is working via IPs^MLCK pathway 115. Also, when
we examined the time tension data, the observation that Ang II develops tension over
minutes rather than seconds suggests a late phase secondary pathway involving PKC.
In rat brain and rat-tail artery, PKC can also activate PLD, which in turn cleaves
phosphatidylcholine to yield choline and PA. Stimulation of ai-adrenoreceptors activates
PKC via the second messenger, DAG. However, ai mediated PLD activation appears
not to involve activation of PKC, since it is not blocked by PKC inhibitors .
In our study, we were further interested in determining whether Ang II induced tension is
mediated via PLD, resulting in the activation of PKC. In the literature, there is definite
evidence that Ang II response is coupled to heterotrimeric G-protein Gai2pY activating
PLD that provides the cell a secondary source of DAG 43. DAG is an important activator
of PKC in vascular smooth muscle. Because there are multiple plasma membrane
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substrates (i.e., phosphatidylinositol and phosphatidylcholine) that are involved in the
production of DAG, we wanted to use a technique that would isolate the specific activity
of PLD.
Since transphosphatidylation is catalyzed by PLD and not by PLC, this property
provides the basis for a novel methodology to distinguish PLD from PLC. In several
cells, phosphatidylethanol is formed when cells are exposed to specific agents in the
presence of ethanol (0.1 to 2%) and when measured, phosphatidylethanol (PEt) is formed
with rates similar to those of choline and PA. Because of metabolic stability, PEt
formation can be used to detect PLD activity in systems where PA does not accumulate
due to rapid dephosphorylation, like the rat-tail artery 29 .
After showing PKC involvement in angiotensinergic-coupled contraction, we
conducted the biochemical experiment mentioned above with Ang II in the presence of
ethanol. The transphosphatidylation reaction induced a > 3-fold increase in the
production of PEt in the rat-tail indicative of PLD activity (Fig. 25). This suggests that
Ang II induced tension is linked to the activation of PLD in the plasma membrane via
heterotrimeric G protein (Gai2py ) as suggested by Ushino et al"Also, Hong Gu et al.
showed similar PLD activity in the rat-tail using norepinephrine, a non-selective ccadrenergic agonist 92. Freeman and Tallant also suggested PLD activation linked to ATi
receptor activation using angiotensin-(2-8)-peptide in the rat-aortic smooth muscle cells
116

. The fact that we conducted our experiments in intact rat-tail artery is significant.

Most published studies dealing with PLD and PKC were conducted in HL-60
granulocytes123, and lymphocytes124, aortic cultured smooth muscle cells and other
smooth muscle cell lines 125 .
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The results of the present study show that: (1) a i-adrenoreceptor stimulation is
the major receptor mediating contraction in the rat-tail artery; (2) Blockade of PKC with
either calphostin C and chelerythrine on Ang II induced tension imply PKC mediated
involvement in the development of tension during the late phase of vascular smooth
muscle contraction; (3) Ang II response is coupled to PLD in the rat-tail arteries.
Clearly, we confirmed that rat-tail vascular smooth muscle is stimulated to
contract by activation of ai-adrenoreceptors and ATi receptors. These data imply that
there is a difference in receptor density and/or a different transduction pathway. The
complexity of adrenergic and angiotensinergic signaling is due, in part, to the ability of
the individual subtypes to couple to different effectors via distinct G proteins 93. Even
though, the rat-tail artery Ang II induced tension is minimal when compared with PHE
induced tension, the developed tension amplifies the activity of protein kinase C.
Whereas, PHE induced tension potentiate the IPs-Ca+2 dependent pathway independent of
PKC in the development of tension in the rat-tail (Figure 39).
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Figure 39: Signal transduction mechanism of oti-adrenergic and ATVangiotensinergic
induced tension development in rat-tail artery. Protein kinase C involvement is greater
via the AT] receptor than the aj-adrenergic receptor pathway. PLC, phospholipase C;
PIP, phosphoinositol phosphate; IP3, inositol trisphosphate; DAG, diacylglycerol; PA,
phosphatidic acid; C, choline; PC, phosphatidylcholine; PLD, phospholipase D; PKC,
protein kinase C; SR, sarcoplasmic reticulum, cmod, calmodulin; MLCK, myosin light
chain kinase; MLCP, myosin light chain phosphatase; CPI-17, myosin light chain
phosphatase inhibitor; and Ca , calcium.
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Peripheral ai-adrenoreceptors are located on both vascular and non-vascular
smooth muscle (prostrate, vas deferens, heart or liver) where activation of the receptor
results in contraction. Investigations employing functional, radioligand binding and
molecular methods have demonstrated the existence of a-adrenergic receptors in vascular
smooth muscle from several species, including rat, rabbit, dog and human

56,57,58

. In

general, establishing the ct|- and a2-adrenergic mediating vasoconstriction in a particular
vascular bed has been hampered, amongst others, by: (a) the lack of highly selective
agonists and/or antagonists; (b) the co-existence of multiple adrenergic subtypes; and (c)
regional differences in the distribution and density.
To rule out the involvement of imidazoline receptors, moxonidine (Mox) was
tested. We compared the concentration-response curve for moxonidine to that of a
selective a.i-adrenergic receptor agonist, phenylephrine. Both compounds showed almost
identical concentration-response curves with similar Emax values and closely related EC50
values, suggesting that both compounds may be acting at the same receptor. There are
only two reports of moxonidine acting at aj receptors in the literature. Raasch et al..
reported that moxonidine (100 pM) increases inotropy by 20-30% in rat atria and this
effect could be antagonized by prazosin, suggesting an a. 1-adrenergic effect100. In
rabbits, moxonidine acts as an agonist at alphai receptors in isolated aorta, pulmonary
artery and vena cava. There is no published report of moxonidine acting as a ajadrenergic agonist in the rat vasculature. Since it is possible for a drug to act as an
agonist in one species of animal and as an antagonist at the same receptor in another
species. There are several investigators who report that moxonidine has affinity for 0,2receptors, and postsynaptic cc2-receptors have been reported to be mediate the initial
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elevation in arterial pressure (AP) after intravenous administration of moxonidine in
animals. Our results confirm the involvement of postsynaptic (X2-adrenergic receptors in
the contractile response to moxonidine, since this response could be partially blocked by
yohimbine and efaroxan at 100 nM and higher doses. The contractile response was more
sensitive to oti-adrenergic blockers, since inhibition could be seen at 1 nM or higher
doses of prazosin and 10 nM or higher doses of urapidil. The fact that the contractile
response is sensitive to two structurally different ai inhibitors at nanomolar doses,
strongly suggests that oti-receptors are involved. A combination of prazosin and
yohimbine had a greater blocking effect than either drug alone, suggesting that both oiiand a,2-adrenergic receptors are involved in the contractile response. To further confirm
the involvement of aj-adrenergic receptors in moxonidine effect on rat-tail artery, we
decided to construct concentration-response curves for both phenylephrine and
moxonidine in the presence of three separate doses of prazosin. With increasing
concentration of antagonist, prazosin, curves for moxonidine and phenylephrine showed
classical right-shift, competitive inhibition. Construction of a Schild plot yielded pA2
values of 9.35 and 10.2 for moxonidine and phenylephrine, respectively. These values
are in close agreement with each other and with values reported for phenylephrine (pA2
within 7 to 10.0)

101,102

. It would thus appear that the higher pA2 values in the rat-tail

arteries suggest that a i-adrenergic receptors play a greater role in vasoconstriction and
Mox is showing a\ adrenergic receptor activation in the rat-tail.
We further compared responses to moxonidine with responses to clonidine, a
known selective (X2 adrenergic agonist. Our time tension data showed that the initial rate
of response for Mox is identical to clonidine.
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This is in agreement with the

pharmacological data, which showed inhibition of Mox induced tension in the presence
of yohimbine, a selective ot2-adrenergic antagonist. But, this finding does not clearly
answer our question. Also, in time tension data, the maximum tension response for Mox
is identical to PHE. This implies that Mox is activating a similar signal transduction
pathway to PHE. Published results indicate that PEC is the major effector enzyme
involved in the inositol-signaling pathway, leading to tail artery contraction 45. When,
we used PI-PEC inhibitor U73122, the data showed inhibition of Mox induced tension
similar to PHE. Our data suggest that moxonidine binding to the cti-adrenergic receptor
is coupled to PEC similar to phenylephrine.
Recently Schafer et al., identified the presence of fi receptor in the male Wistar
rat heart

117

. No studies have been conducted in the Sprague-Dawley rat-tail artery. Our

current Mox data imply no significant role off receptor response in the rat-tail. The
pharmacological data with efaroxan, a partial band «2 receptor antagonist, show
inhibition, but data with yohimbine show attenuation equally, implying a2-adrenergic
receptor affinity

117,118

. Further work is needed to elucidate the role of b receptor in

vascular smooth muscle.
Summary and Conclusion
In summary, our study demonstrates that the ct]-adrenergic receptor is the major
receptor for mediating contraction in the rat-tail artery. Postsynaptic a2—adrenergic
receptor also plays a significant role in rat-tail artery contraction but to a lesser extent so
than oti-adrenergic receptors. Similarly, angiotensin (ATj) receptors are involved in rattail artery contraction but to a lesser extent than adrenergic receptors. Our data did not
reveal a role for b receptor in rat-tail artery contraction. The data further suggest that
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PKC plays a greater role in the contractile response mediated by Ang II receptor than the
a i-adrenergic receptor. The ATj receptor response seems to affect PLD, resulting in
PKC effects downstream. We finally, show that moxonidine, a known Ii/a2-adrenergic
agonist, mediates rat-tail artery contraction via the activation of ot2-and ct]-adrenergic
receptors, and not via specific imidazoline receptors (Figure 40).
In conclusion, a-adrenergic receptors are the prime mediators of vascular
contraction, with ATi receptors playing a minor role in rat-tail artery.
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Figure 40: Diagram shows the signal transduction pathways activated by moxonidine in
the rat-tail vascular smooth muscle. Mox, moxonidine, II, imidazoline receptor, ccRl,
alpha-1-adrenergic receptor; aR2, alpha-2-adrenergic receptor; PIP2,
phosphatidylinositol 4,5-bisphosphate; Gaq/(3y, heterotrimeric G-protein; Gi, inhibitory
G-protein; ATP, adenosine trisphosphate; cAMP, cyclic adenosine monophosphate;DAG,
diacylglycerol, IP3, inositol trisphosphate; PLCpi, phospholipase C-betal; SR,
sarcoplasmic reticulum, and Ca , calcium.
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Future Directions
Despite the enormous progress already made in identification and analysis of
adrenergic and angiotensinergic receptors, there are still many important questions to be
answered. Development of more selective agonists and antagonists will allow a clearer
understanding of the tissue distribution and functional roles of individual subtypes.
Adrenergic receptors are the most widely studied family of receptors. Alpha]-adrenergic
receptors have major physiological importance in the control of blood pressure, blood
flow, digestion, airways, reproduction, pupil diameter, endocrine and metabolic
processes. Alpha2~adrenergic receptors are important regulators of sympathetic tone.
neurotransmitter release, and blood pressure. ATi receptor regulates blood pressure and
vascular resistance. Inhibitors like prazosin and clonidine have been used to treat
hypertension, but side effects like sedation, dry mouth or rebound hypertension have
pushed investigators to elucidate other receptors, and drugs that can minimize these
limitations. Besides acting on a2-adrenergic receptors, several new compounds like
rilmenidine and moxonidine have been shown to display affinity at the imidazoline fbinding sites. The argument supporting that hypotension is induced via a selective action
at imidazoline 11-binding sites, presumes that compounds such as moxonidine and
rilmendine act preferentially through this site. However, based on our studies, the
involvement of 11-binding sites in controlling vasoconstriction or vascular resistance in
the rat-tail remains unclear. The fact that more that one receptor may be involved in
regulating one particular physiological function does not limit the therapeutic potential of
novel subtype-selective drugs for adrenergic and angiotensinergic receptors. Finally, rat
lacking a.2-adrenergic receptor subtypes would be a useful animal model for determining
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the function of imidazoline. Further pharmacological and molecular studies with ATi
and aj-adrenergic receptor subtypes will allow for a better and more complete
understanding of the signal transduction pathways in vascular smooth muscle physiology.
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